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Human African trypanosomiasis (HAT), Chagas disease and leishmaniasis, which are caused by the
trypanosomatids Trypanosoma brucei, Trypanosoma cruzi and Leishmania species, are among the most
deadly neglected tropical diseases. The development of drugs that are active against several trypano-
somatids is appealing from a clinical and economic viewpoint, and seems feasible, as these parasites
share metabolic pathways and hence might be treatable by common drugs. From benzonapthyridine 1,
an inhibitor of acetylcholinesterase (AChE) for which we have found a remarkable trypanocidal activity,
we have designed and synthesized novel benzo[h][1,6]naphthyridines, pyrrolo[3,2-c]quinolines, azepino
[3,2-c]quinolines, and pyrano[3,2-c]quinolines through 2e4-step sequences featuring an initial multi-
component Povarov reaction as the key step. To assess the therapeutic potential of the novel compounds,
we have evaluated their in vitro activity against T. brucei, T. cruzi, and Leishmania infantum, as well as their
brain permeability, which is of speciﬁc interest for the treatment of late-stage HAT. To assess their po-
tential toxicity, we have determined their cytotoxicity against rat myoblast L6 cells and their AChE
inhibitory activity. Several tricyclic heterofused quinoline derivatives were found to display an inter-
esting multi-trypanosomatid proﬁle, with one-digit micromolar potencies against two of these parasites
and two-digit micromolar potency against the other. Pyranoquinoline 39, which displays IC50 values of
1.5 mM, 6.1 mM and 29.2 mM against T. brucei, L. infantum and T. cruzi, respectively, brain permeability,
better drug-like properties (lower lipophilicity and molecular weight and higher CNS MPO desirability
score) than hit 1, and the lowest AChE inhibitory activity of the series (IC50 > 30 mM), emerges as an
interesting multi-trypanosomatid lead, amenable to further optimization particularly in terms of its
selectivity index over mammalian cells.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Neglected tropical diseases (NTDs) are a group of 17 infectious
diseases that globally affect more than 1 billion people from 149z-Torrero).
r Masson SAS. This is an open accecountries [1]. Not only do NTDs cause a huge health impact, both in
terms of disability-adjusted life years (DALY, 26 million DALYs) and
mortality (534,000 deaths annually), but they also have harmful
effects on the overall economic productivity of developing coun-
tries where these diseases are endemic, which become inexorably
trapped in an unbreakable cycle of poverty [2e4].
Among NTDs, vector-borne kinetoplastid diseases aress article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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trypanosomiasis) and human African trypanosomiasis (HAT or
sleeping sickness) ranking ﬁrst, ﬁfth and sixth, respectively, in
number of associated deaths [2]. Their causative agents are trypa-
nosomatid parasites that are transmitted to humans through the
intervention of an infected insect vector: Trypanosoma brucei gam-
biense and T. brucei rhodesiense (accounting for 98% and 2% of cases
of HAT, respectively) spread through the bite of blood-feeding tsetse
ﬂies; Trypanosoma cruzi (for Chagas disease) transmitted most
commonly through contact with the faeces of a blood-sucking tri-
atomine bug (the so-called kissing bug); and different Leishmania
species, prominently Leishmania donovani and Leishmania infantum
(for visceral leishmaniasis), transmitted by the bite of female phle-
botomine sand ﬂies. In the absence of treatment, these diseases are
frequently fatal, with their mortality being associated to particular
stages or forms of the disease. In the case of HAT, after an initial
hemo-lymphatic stage characterized by nonspeciﬁc clinical symp-
toms, parasites can cross the bloodebrain barrier (BBB) and invade
the central nervous system (CNS), giving rise to an array of severe
neurologicalmanifestations that includeprofound sleepdisruptions
and eventually coma and death. The initial phases of Chagas disease
are usuallyasymptomatic or associatedwithnon-speciﬁc symptoms
of fever, malaise, or lymph node enlargement, but in about 30% of
patients it evolves into a chronic phase, usually characterized by
cardiomyopathy, and is a major cause of premature heart failure in
Latin America. The most severe manifestation of leishmaniasis is
visceral form, which leads to hepatosplenomegaly, progressive
anaemia, and ultimately death in most cases.
These diseases are usually conﬁned to rural areas of endemic
countries (sub-Saharan Africa for HAT, mainly Central and South
America for Chagas disease, and Middle East and Asia, East Africa,
Central and South America and Southern Europe for leishmaniasis).
However, climate changes due to global warming, whichmay result
in an extension of the insect vector habitats, as well as international
travel and immigration patterns may expand the geographical
impact of these infectious diseases, thereby increasing the popu-
lation at risk [5]. Travel to and immigration from endemic countries
have made Chagas disease and several forms of leishmaniasis
emerging infections in the United States (both infections), and
Spain and Japan (Chagas disease) [6,7].
The current therapies against HAT, Chagas disease and leish-
maniasis suffer from important shortcomings. HAT ﬁrst-stage
treatments rely on pentamidine and suramin, which require
parenteral administration and are ineffective against the second
stage. Stage 2 HAT can be treated by painful intravenous adminis-
tration of the arsenical drug melarsoprol, which may lead to fatal
reactive encephalopathy in 5e10% of patients, or with eﬂornithine,
which is much safer but requires intravenous administration and
hospitalization [8]. Toxicity is also a major issue with the approved
drugs against Chagas disease, the nitroderivatives benznidazole
and nifurtimox, and with some of the drugs used for the treatment
of visceral leishmaniasis (pentavalent antimonials, amphotericin B,
paromomycin and miltefosine). Apart from complicated long
courses of treatment, in most cases parenteral administration is
required. In addition, the emergence of resistance to these drugs in
areas of high transmission further challenges their clinical appli-
cation [6,8e13].
In the absence of preventive or therapeutic vaccines and
rigorous control of insect vectors [5,14], the development of novel
chemotherapies against these infectious diseases, with appropriate
efﬁcacy and safety proﬁles, is desperately needed [15,16]. Besides
combinations of approved antiprotozoan drugs or repurposing of
known drugs with other indications [8,14,15], increasing research
efforts are beingmade to design novel chemical entities that hit one
or several biological targets which play a key role in the biology ofthe parasite and are sufﬁciently different from those in the
mammalian host cells as to enable selective toxicity [5,9,17e23].
However, while we are gaining a better understanding of the
relevant parasite targets, phenotypic whole cell screening of novel
compounds or chemical libraries remains a very successful
approach for anti-protozoan drug discovery [8,24,25]. Thus, anti-
protozoan drug pipelines are being enriched through drug dis-
covery campaigns involving the synthesis of novel chemical entities
and their biological evaluation against the selected parasites
[26e28]. Of particular interest are those compounds that can be
active against several protozoan parasites [25,29e31], as several
NTDs usually coexist in endemic countries [1]. The trypanosomatid
parasites that cause HAT, Chagas disease and leishmaniasis are
taxonomically related, have similar structural and biochemical
features, and seem to share many of their metabolic pathways [14],
thereby rendering them especially amenable to modulation by
common drugs. Indeed, several structural families featuring a 4-
aminoquinoline moiety have been recently reported to display a
multi-protozoan proﬁle, namely trypanocidal and antiplasmodial
activity [32e35].
The use of multicomponent reactions [36] appears to be a very
useful strategy to rapidly build new hits in a modular manner. This
approach is having a tremendous impact in modern medicinal
chemistry. Apart from considerably speeding the process and
manufacture of some drugs [37], it is especially relevant in drug
discovery. It allows the preparation of new scaffolds and their
straightforward decoration, and also facilitates the hit to lead
transition and pharmacological issues [38,39]. We have recently
reported the synthesis and acetylcholinesterase (AChE) inhibitory
activity of a series of 1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridines
such as 1 (Fig. 1), which are prepared using a multicomponent
Povarov reaction as the key step [40]. This transformation requires
a cyclic enamide as an activated oleﬁn, which affords the ring A of 1
(Fig. 1), an aromatic aldehyde, which affords the substituent at
position 5, and an aniline, which affords the ring C with the sub-
stituent at position 9. Because the tricyclic scaffold of the benzo[h]
[1,6]naphthyridine system of 1 contains a 4-aminoquinoline motif
and a side chain with a second protonatable nitrogen atom, we
inferred that this compound might display some anti-protozoan
activity. Indeed, the outstanding IC50 value of 3.33 mM against
T. brucei that we have found for 1 has conﬁrmed our initial
assumption. In light of this, and relying on the synthetic versatility
of the multicomponent Povarov reaction [41,42], which might
enable the modiﬁcation of ring A and the substituents at positions
1, 5 and 9 of benzonaphthyridine 1 by simply changing the starting
materials, we planned the synthesis of a series of analogues of 1 and
their evaluation against the trypanosomatids that cause HAT,
Chagas disease and leishmaniasis.
Here, we report i) the synthesis of novel benzo[h][1,6]naph-
thyridine-, pyrrolo[3,2-c]quinoline-, azepino[3,2-c]quinoline-, and
pyrano[3,2-c]quinoline-based analogues of 1 with different sub-
stituents at rings A, B, and C, as well as some quinoline derivatives
resulting from opening of ring A of some of these tricyclic scaffolds;
ii) their evaluation against T. brucei, T. cruzi and L. infantum; iii) and
the assessment of their cytotoxic activity against rat myoblast L6
cells and their AChE inhibitory activity. Also, to determine their
potential usefulness for late-stage HAT, the ability of the novel
compounds to cross the BBB has been evaluated in vitro using a
parallel artiﬁcial membrane permeability assay (PAMPA-BBB).
2. Results and discussion
2.1. Design and synthesis of the target compounds
Compound 1 is a rather quite lipophilic molecule, with a
Fig. 1. Design of the novel benzonaphthyridines 2 and 3 and other heterofused quinoline analogues from compound 1.
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commonly accepted threshold for good oral bioavailability [44]. In
order to decrease lipophilicity, we ﬁrst envisaged the synthesis of
compound 2, i.e. the N-deethylated derivative of 1, and its isomer 3
(Fig. 1 and Schemes 1 and 2), in which the chloro and aminomethyl
substituents at the para position of the phenyl substituent and at
position 9, respectively, were interchanged. Interestingly, both
analogues turned out to be more potent against T. brucei than hit 1
(Fig. 1, see Section 2.2), especially compound 3, which was 3-fold
more potent, albeit still too lipophilic (log P ¼ 5.89).
In this regard, we next envisioned a series of modiﬁcations
around the structure of compound 3, aimed at improving drug
likeness and deriving structureeactivity relationships ﬁrst against
T. brucei, and then against T. cruzi and L. infantum. Because removal
of the benzyl group at position 1 of compound 3 should lead to a
signiﬁcant decrease of both lipophilicity andmolecular weight and,
hence, to improved drug likeness, we planned the synthesis of the
N1-unsubstituted derivative 31 and its analogues resulting from
ring contraction and ring expansion (30 and 32, respectively,
Scheme 3), isomerization of the chlorine substituent from position
9 to position 8 (33, Scheme 3), and NH/ O bioisosteric replace-
ment (39, Scheme 5), using the corresponding nitriles as the im-
mediate precursors. Moreover, to assess the relevance of the 4-
aminomethylphenyl substituent at the B-ring, we decided to
study the biological activity of the nitrile precursors (i.e. 26e29 and
38, Schemes 3 and 5), as well as that of compounds 42 and 43, in
which the 4-aminomethylphenyl group at the B-ring of compound
39 was replaced by a 2-furyl- or 2-thienyl- substituent (Scheme 6).
During the synthesis of the target tricyclic heterofused quinoline
compounds some byproducts arising from opening of the A-ring
were obtained (see below) and, eventually, converted into addi-
tional target compounds featuring cyano, hydroxy or amino groupsScheme 1. Reagents and conditions: (i) 5, 6, Sc(OTf)3, CH3CN, rt, 5 min; then, 4, CH3CN, rt, 3
(iv) (EtO)3SiH, Zn(OAc)2, THF, rt, 30 min; then, 9, THF, 65 C, 48 h, 66%.at the side chain (i.e. 35, 44, 45, 47, 49 and 50, Schemes 4, 6 and 7).
The synthesis of compound 2 was carried out by the four-step
sequence depicted in Scheme 1. The multicomponent Povarov re-
action between the known unsaturated lactam 4 as the activated
oleﬁn [45,46], and commercially available 4-chlorobenzaldehyde,
6, and aniline 5, bearing an N-Boc-protected aminomethyl side
chain, under Sc(OTf)3 catalysis in acetonitrile, followed by DDQ
oxidation [47] of the resulting diastereomeric mixture of octahy-
drobenzonaphthyridines 7 afforded compound 8 in 47% overall
yield, after silica gel column chromatography puriﬁcation. N-Boc
deprotection of 8, followed by reduction of the resulting lactam 9
with (EtO)3SiH under Zn(OAc)2 catalysis [48], and silica gel column
chromatography puriﬁcation afforded the target benzonaphthyr-
idine 2, in 29% overall yield for the last two steps (Scheme 1).
The synthesis of compound 3 required only 3 steps, starting
with a multicomponent Povarov reaction between the enamide 4,
4-chloroaniline, 10, and the aromatic aldehyde 11, bearing a 4-
cyano group as the precursor of the aminomethyl side chain. DDQ
oxidation of the resulting diastereomeric mixture of octahy-
drobenzonaphthyridines 12, followed by simultaneous LiAlH4
reduction of the lactam and nitrile functionalities of compound 13
afforded the target benzonaphthyridine 3 in low overall yield, after
silica gel column chromatography puriﬁcation (Scheme 2).
For the synthesis of the N1-debenzylated analogues 30e33 we
used a 4-step protocol that involved an initial multicomponent
Povarov reaction between chloroanilines 10 or 17, cyano aldehyde
11 and commercially available N-Boc-protected cyclic enamines
14e16, followed by DDQ oxidation, N-Boc acidic deprotection, and
ﬁnal LiAlH4 reduction of nitriles 26e29 (Scheme 3). After silica gel
column chromatography puriﬁcation, the target compounds 30, 31,
32, and 33 were obtained in 20%, 41%, 22%, and 39% overall yield,
respectively.days; (ii) DDQ, CHCl3, rt, overnight, 47% overall; (iii) 4M HCl/dioxane, rt, overnight, 44%;
Scheme 2. Reagents and conditions: (i) 10,11, Sc(OTf)3, CH3CN, rt, 5 min; then, 4, CH3CN, rt, 3 days; (ii) DDQ, CHCl3, rt, overnight, 35% overall; (iii) LiAlH4, THF, reﬂux, overnight, 22%.
Scheme 3. Reagents and conditions: (i) 10 or 17, 11, Sc(OTf)3, CH3CN, rt, 5 min; then, 14, 15 or 16, CH3CN, rt, 3 days; (ii) DDQ, CHCl3, rt, overnight, 59% (22), 69% (23), 79% (24), and
62% (25) overall; (iii) 4M HCl/dioxane, rt, overnight, 46% (26), 68% (27), 51% (28), and 94% (29); (iv) LiAlH4, THF, reﬂux, overnight, 74% (30), 87% (31), 55% (32), and 67% (33).
Scheme 4. Reagents and conditions: (i) 4M HCl/dioxane, rt, overnight, 90%.
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amount (17% yield) of ring-open by-product 34 (Scheme 4) was also
formed. This compound was subjected to the standard acidic con-
ditions for N-Boc deprotection, affording amine 35 in 90% yield
(Scheme 4).
The synthesis of pyranoquinoline 39 was envisaged through a
three-step sequence, analogous to that used for compound 3, but
starting from 3,4-dihydro-2H-pyran, 36, as the activated oleﬁn for
the Povarov reaction instead of the enamide 4 (Scheme 5).
Because we wanted to assess the inﬂuence on anti-protozoan
activity of the degree of oxidation of the B-ring of the hetero-
fused quinoline compounds, at this point we decided to isolate the
tetrahydroquinoline compound resulting from the Povarov reac-
tion, before performing the oxidation to the ﬁnal quinoline deriv-
ative. Thus, after the reaction between the cyclic enol ether 36, the
aniline 10 and the aldehyde 11, the crude product was puriﬁed by
silica gel column chromatography to obtain a 1:1 diastereomeric
mixture 37 in 95% yield. After a second column chromatography
from this material, a sample of the all-cis-diastereoisomer, all-cis-37, was isolated to be subjected to biological evaluation (see below).
Eventually, the pyranoquinoline 39 was obtained in 23% overall
yield by DDQ oxidation of the diastereomeric mixture 37 to the
quinoline derivative 38, followed by LiAlH4 reduction of the nitrile
to an aminomethyl group (Scheme 5).
Analogously to the synthesis of 39, starting from the cyclic enol
Scheme 5. Reagents and conditions: (i) 10, 11, Sc(OTf)3, CH3CN, rt, 5 min; then, 36, CH3CN, rt, 3 days, 95% (1:1 diastereomeric mixture); (ii) DDQ, CHCl3, rt, overnight, 41%; (iii)
LiAlH4, THF, reﬂux, overnight, 59%.
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furan-2-carboxaldehyde and thiophene-2-carboxaldehyde, 40, and
41, respectively, the target pyranoquinoline derivatives 42 and 43,
substituted at position 5with a 2-furyl or 2-thienyl group instead of
an aminomethylphenyl substituent, were obtained in 27% and 40%
yield, respectively, together with signiﬁcant amounts of the ring-
open byproducts 44 (30% yield) and 45 (24% yield), respectively
(Scheme 6).
Finally, the Mitsunobu reaction of compound 45 with N-(tert-
butyldimethylsilyloxy)-4-methylbenzenesulfonamide followed by
treatment with CsF in acetonitrile afforded nitrile 47 in 84% overall
yield, after silica gel column chromatography puriﬁcation. More-
over, alcohol 45was converted viamesylate into the corresponding
amines 49 and 50 in 31% and 16% overall yield, respectivelyScheme 6. Reagents and conditions: (i) 10, 40 or 41, Sc(OTf)3, CH3CN, rt, 5 min; then, 36, CH
30% (44), 40% (43) and 24% (45) overall.
Scheme 7. Reagents and conditions: (i) N-(tert-butyldimethylsilyloxy)-4-methylbenzenesulf
(iii) MsCl, Et3N, 0 C, 30 min; (iv) pyrrolidine or Et2NH, K2CO3, DMF, 85 C, overnight, 31%(Scheme 7).
All the compounds to be subjected to biological evaluation,
except 37, were transformed into the corresponding hydrochloride
or dihydrochloride salts, and were chemically characterized
through IR, 1H and 13C NMR spectra, HRMS and HPLC purity analysis
and elemental analysis.
2.2. Biological proﬁling of the novel heterofused quinoline
compounds and ring-open analogues
2.2.1. In vitro activity against T. brucei
As previously mentioned, we ﬁrst evaluated the activity of 1, a
compound that we had developed as an inhibitor of AChE [40], and
the novel heterofused quinoline and ring-open analogues in vitro3CN, 50 C (for 42) or 80 C (for 43), 3 days; (ii) DDQ, CHCl3, rt, overnight, 27% (42) and
onamide, PPh3, DEAD, toluene, THF, rt, 5 min; (ii) CsF, CH3CN, 60 C, 2.5 h, 84% overall;
(49), 16% (50) overall.
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a reference compound. We also investigated their brain perme-
ability to assess their potential usefulness in late-stage HAT. To
determine potential toxic effects, their cytotoxicity against rat
skeletal myoblast L6 cells and AChE inhibitory activity, whichmight
result in cholinergic side-effects, were also evaluated.
All the novel heterofused quinoline derivatives featuring a
protonatable aminomethylphenyl group at the B-ring, including the
benzo[h][1,6]naphthyridines 2, 3, 31 and 33, the pyrrolo[3,2-c]
quinoline 30, the azepino[3,2-c]quinoline 32, and the pyrano[3,2-c]
quinoline 39, were found to be 1.5e4-fold more potent than hit 1
and 2e5-fold more potent than the reference compound nifurti-
mox, with IC50 and IC90 values in the range 0.92e2.44 mM and
1.19e3.48 mM, respectively (Table 1). In contrast, their nitrile pre-
cursors 26e29, 37, and 38, as well as the 5-(2-furyl)- and 5-(2-
thienyl)-substituted pyrano[3,2-c]quinolines 42 and 43, all of
them bearing a neutral group at the B-ring, were clearly less potent.
This highlights the relevance for trypanosomal activity of the
presence of a protonatable group at the side chain of the substit-
uent at the B-ring of the tricyclic heterofused quinoline derivatives.
Within the most potent tricyclic heterofused quinoline de-
rivatives, the best substitution pattern for activity against T. brucei
seems to involve i) Bn-N > O > NH at position 1 of the A-ring, with
compound 3 being 1.5- and 2.4-fold more potent than 39 and 31,
respectively, ii) a ﬁve-membered A-ring, with compound 30 being
2.5-fold more potent than 31 and 32, bearing a six- and seven-
membered A ring, respectively, and iii) the presence of the chlo-
rine atom at position meta relative to the quinoline nitrogen atom,
with compound 33 being 2-fold more potent than 31.
As in the tricyclic heterofused quinoline derivatives, the pres-
ence of a protonatable nitrogen atom at the side chain of ring-open
quinoline analogues seems to be play a role in the activity of theseTable 1
Trypanocidal (T. brucei), cytotoxic and anticholinesterase activity and BBB permeability o
Compd T. brucei
IC50 (mM)
T. brucei
IC90 (mM)
L6 cells
IC50 (mM
1 3.33 ± 0.18 4.39 ± 0.04 7.08 ± 0.
2 2.10 ± 0.07 2.90 ± 0.02 7.99 ± 0.
3 1.00 ± 0.03 1.19 ± 0.02 6.78 ± 1.
26 >30 >30 d
27 6.07 ± 0.54 10.5 ± 0.2 38.8 ± 1.
28 17.3 ± 2.1 28.6 ± 6.7 d
29 >30 >30 d
30 0.92 ± 0.05 1.57 ± 0.03 2.54 ± 0.
31 2.44 ± 0.13 3.48 ± 0.05 8.92 ± 0.
32 2.33 ± 0.12 3.35 ± 0.05 7.02 ± 0.
33 1.25 ± 0.05 2.12 ± 0.02 3.07 ± 0.
35 4.16 ± 0.07 5.61 ± 0.05 20.4 ± 0.
37 >30 >30 d
38 9.61 ± 0.27 13.7 ± 1.0 36.3 ± 8.
39 1.46 ± 0.02 1.77 ± 0.02 7.00 ± 0.
42 21.7 ± 1.2 29.3 ± 0.5 d
43 18.0 ± 0.4 27.6 ± 1.1 d
44 35.7 ± 1.8 70.6 ± 1.5 d
45 28.0 ± 0.7 42.9 ± 1.5 d
47 >30 >30 d
49 3.56 ± 0.17 4.93 ± 0.17 9.44 ± 0.
50 6.33 ± 0.94 12.6 ± 0.9 14.7 ± 2.
nifurtimox 4.4 ± 0.7h 32.0 ± 1.
a In vitro activity against bloodstream form of T. brucei (pH 7.4), rat myoblast L6 cells, an
or enzyme activity by 50% (IC50) and 90% (IC90, for T. brucei). Data are the mean of tripli
b SITb: selectivity index as the ratio of cytotoxic to anti-T. brucei IC50 values.
c Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ±
d Not determined.
e Taken from ref. [40], involving the same experimental conditions.
f 45% Inhibition at 30 mM (the IC50 could not be determined).
g 54% Inhibition at 30 mM (the IC50 could not be determined).
h Taken from Ref. [49].compounds against T. brucei, with amines 35, 49, and 50 exhibiting
IC50 values around 5 mM (Table 1), whereas compounds 44, 45, and
47, with neutral hydroxy or cyano groups at the side chain were
clearly less potent (IC50 > 25 mM).
2.2.2. Brain permeation
Brain penetration is a desirable property for novel drugs against
HAT, as it will make them effective against the late-stage disease,
when parasites have invaded the CNS. Thus, the brain passive
permeability of the novel compounds was evaluated in vitro
through the widely used PAMPA-BBB method [50], which is based
on the use of a porcine brain lipid extract as an artiﬁcial BBB model.
The novel compounds had in vitro permeabilities (Pe) clearly above
the threshold established for a high BBB permeation, i.e. CNSþwith
Pe (106 cm s1) > 5.25, with the exceptions of compounds 31, 33,
and 42, for which an uncertain BBB permeation was predicted
(Table 1).
Apart from a high brain passive permeability, a low P-glyco-
protein (P-gp) efﬂux is a highly desirable property to ensure target
engagement in the CNS. A number of knowledge-based approaches
have emerged to assist the early phases of the drug discovery
process, by addressing different aspects related with pharmacoki-
netic and pharmacodynamic properties to enhance the likelihood
of deriving candidates with appropriate drug-like properties [51].
For compounds intended to act within the CNS, some molecular
descriptor guidelines recommend to maintain topological polar
surface area (TPSA) < 90 Å2 (preferably < 70 Å2) and the number of
hydrogen bond donors (HBD) < 2 to maximize the probability of
evading P-gp efﬂux [52,53]. All of the novel compounds have TPSA
values well below 70 Å2 and most of them also have a HBD
number 2 (Table S1, SupplementaryMaterial), so that they should
be expected to show a low P-gp efﬂux liability.f the novel heterofused quinolines and related compounds.a
)
SITbb Pe (106 cm s1)c
(prediction)
EeAChE
IC50 (mM)
11 2.1 d 0.15 ± 0.01e
25 3.8 d 1.05 ± 0.18
26 6.8 7.4 ± 0.2 (CNSþ) 3.67 ± 0.55
d 6.8 ± 0.3 (CNSþ) 1.19 ± 0.15
7 6.4 14.3 ± 0.1 (CNSþ) 1.13 ± 0.17
d 20.0 ± 1.1 (CNSþ) 2.20 ± 0.30
d 16.2 ± 0.1 (CNSþ) 3.27 ± 0.43
92 2.8 7.4 ± 2.6 (CNSþ) 0.87 ± 0.08
25 3.7 4.6 ± 0.2 (CNS±) 0.97 ± 0.02
27 3.0 11.6 ± 0.2 (CNSþ) 1.20 ± 0.13
66 2.5 4.0 ± 1.0 (CNS±) 0.44 ± 0.04
4 4.9 18.3 ± 0.6 (CNSþ) d
d 7.0 ± 0.7 (CNSþ) d
1 3.8 29.7 ± 3.8 (CNSþ) 2.70 ± 0.45
19 4.8 15.5 ± 1.8 (CNSþ) >30f
d 3.5 ± 0.4 (CNS±) 16.3 ± 1.5
d 14.4 ± 1.6 (CNSþ) 9.39 ± 0.82
d 10.3 ± 1.5 (CNSþ) d
d 28.4 ± 1.2 (CNSþ) d
d 17.9 ± 1.1 (CNSþ) d
14 2.7 12.9 ± 0.1 (CNSþ) ~30g
3 2.3 20.9 ± 0.5 (CNSþ) d
1 7.3 d d
d Electrophorus electricus AChE, expressed at the concentration that inhibited growth
cate experiments ± SEM.
SD of three independent experiments.
Table 2
In vitro activity of the novel heterofused quinolines and related compounds against
epimastigotes of Trypanosoma cruzi and promastigotes of Leishmania infantum.a
Compd T. cruzi
IC50 (mM)
L. infantum
IC50 (mM)
SITcb SILic
2 38.1 ± 9.5 8.1 ± 1.9 0.2 1.0
3 9.5 ± 2.5 31.1 ± 2.9 0.7 0.2
26 >150 >200 d d
27 147 ± 19 15.3 ± 3.6 0.3 2.5
28 64.6 ± 12.5 13.7 ± 2.2 d d
29 39.4 ± 0.2 19.0 ± 3.0 d d
30 37.3 ± 11.0 6.5 ± 1.4 0.1 0.4
31 50.5 ± 14.3 11.6 ± 2.5 0.2 0.8
32 32.4 ± 0.6 4.8 ± 0.7 0.2 1.5
33 76.1 ± 3.2 13.0 ± 0.6 0.04 0.2
35 78.8 ± 1.7 16.2 ± 4.0 0.3 1.3
37 676 ± 37 >200 d d
38 178 ± 92 23.5 ± 2.4 0.2 1.5
39 29.2 ± 3.7 6.1 ± 0.2 0.2 1.1
42 76.1 ± 7.8 38.4 ± 21.6 d d
43 >250 51.4 ± 2.3 d d
44 29.3 ± 12.0 19.3 ± 11.3 d d
45 51.7 ± 19.4 37.3 ± 2.3 d d
47 51.7 ± 5.1 23.3 ± 5.9 d d
49 35.2 ± 12.6 13.1 ± 5.8 0.3 0.7
50 77.6 ± 11.2 13.6 ± 1.5 0.2 1.1
Benznidazole 36.2 ± 5.1 d 14.1e d
Sb (III)f d 24.3 ± 1.7 d 0.1g
a In vitro activity against epimastigote form of T. cruzi and promastigote form of
L. infantum, expressed at the concentration that inhibited growth by 50% (IC50). Data
are the mean ± SD of duplicate experiments performed at least twice.
b SITc: selectivity index as the ratio of cytotoxic to anti-T. cruzi IC50 values.
c SILi: selectivity index as the ratio of cytotoxic to anti-L. infantum IC50 values.
d Not determined.
e IC50 value against rat myoblast L6 cells ¼ 510 ± 22.
f Potassium antimony (III) tartrate hydrate.
g IC50 value against rat myoblast L6 cells ¼ 3.27 ± 0.24.
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compounds and gain additional insight into their CNS drug-
likeness, we applied the Pﬁzer CNS multiparameter optimization
(CNS MPO) algorithm [54]. This algorithm is based on a set of six
physicochemical parameters, namely lipophilicity (cLogP), calcu-
lated distribution coefﬁcient at pH 7.4 (cLogD), molecular weight,
TPSA, number of HBD, and the pKa value of the most basic centre,
with all these parameters being weighted equally using a desir-
ability score from 0 to 1. Increasing total CNS MPO scores for drugs
has been correlated with increasing probabilities of appropriate
pharmacokinetic and safety attributes, including high passive
permeability and low P-gp efﬂux, amongst others. Particularly,
drugs with CNS MPO desirability scores 4 (in a scale from 0 to 6)
are expected to show a full alignment of the desired pharmacoki-
netic properties [54]. Interestingly, CNS MPO desirability scores  4
have been calculated for 12 out of the 21 novel compounds
(Table S2, Supplementary Material), which supports their potential
usefulness for treating late-stage HAT.
2.2.3. Cytotoxicity and acetylcholinesterase inhibitory activity
To assess potential toxic effects of the novel derivatives, all the
compounds with IC50 values against T. brucei below 10 mM were
subjected to cytotoxicity studies using rat myoblast L6 cells. All the
tested compounds were selective for T. brucei vs mammalian cells
(selectivity indices (SITb) in the range 2.1e6.8 (Table 1), being more
selective than the hit 1 but less selective than nifurtimox
(SITb ¼ 7.3).
Because hit 1was developed as an AChE inhibitor with potential
application against Alzheimer's disease, this kind of activity might
result in unwanted cholinergic side effects if the novel compounds
were used as anti-protozoan agents. We therefore evaluated their
AChE inhibitory activity using Electrophorus electricus AChE
(EeAChE), a widely used and affordable enzyme source for
screening this activity. All the structural modiﬁcations carried out
around the structure of hit 1 led to a decrease in EeAChE inhibitory
activity (3e110-fold). However, despite their decreased AChE
inhibitory activity relative to hit 1, most tested compounds were
more potent against EeAChE than against T. brucei. Only the ben-
zonaphthyridine 3, the pyranoquinoline 39 and the ring-open
quinoline derivative 49 turned out to be more potent against
T. brucei than against EeAChE (4-, >20- and ~8-fold, respectively).
Of note, hit 1 is 6-fold less potent against human recombinant
AChE (hAChE) than against EeAChE (IC50 ¼ 0.15 mM compared with
IC50¼ 0.94 mM) [40]. Even though this might also be the case for the
novel compounds reported here, future lead optimization should
focus on decreasing AChE inhibitory activity and increasing selec-
tivity indices.
2.2.4. In vitro activity against T. cruzi and L. infantum
The occurrence of common metabolic pathways in trypanoso-
matid parasites makes it potentially feasible to develop anti-
protozoan agents endowed with a multi-trypanosomatid proﬁle
[14,55]. Thus, after having conﬁrmed the signiﬁcant activity against
T. brucei of all the novel target heterofused quinoline derivatives
and some of the ring-open analogues and assessed their brain
permeation, cytotoxicity and AChE inhibitory activity, we under-
took the evaluation of all the novel compounds against epi-
mastigote forms of T. cruzi (strain MHOM/ES/2203/BCN590 (Tcl))
and promastigote forms of L. infantum (strain MCAN/ES/92/
BCN722), using benznidazole and potassium antimony (III) tartrate
hydrate as reference compounds.
Most of the tested compounds exhibited activity against T. cruzi,
albeit with two-digit micromolar IC50 values (Table 2). Interest-
ingly, there was a similar SAR proﬁle as had been found with
T. brucei. First, isomerization of the chlorine and aminomethylsubstituents from compound 2 to 3 results in increased potency
against T. cruzi (4-fold). Also, higher potencies were observed for
those tricyclic heterofused quinoline analogues bearing a proto-
natable 4-(aminomethyl)phenyl group at the B-ring, relative to
those bearing a 4-cyanophenyl, 2-furyl, or 2-thienyl groups. Thus,
amines 30, 31, 32, and 39 were 2e6-fold more potent than their
nitrile precursors 26, 27, 28, and 38, respectively, and amine 39was
also 3- and 10-fold more potent than the 5-(2-furyl)- and 5-(2-
thienyl)-substituted derivatives 42 and 43, respectively. The sole
exception was amine 33, which turned out to be 2-fold less potent
than its nitrile precursor 29. Also, within the aminomethylphenyl-
substituted analogues, the order of potencies related to the sub-
stitution at position 1 of the A-ring was: Bn-N > O > NH, with the
N1-benzylated benzonapththyridine 3 being 3- and 5-fold more
potent than pyranoquinoline 39 and N1-unsubstituted benzo-
napththyridine 31. Regarding the size of the A-ring, again the
presence of a ﬁve- or a seven-membered ring A led to increased
potency relative to the derivatives with a six-membered A-ring,
with the pyrroloquinoline 30 and the azepinoquinoline 32 being
1.5-fold more potent than the benzonaphthyridine 31. For this ac-
tivity, unlike against T. brucei, a higher potency seems to arise from
the presence of a chlorine atom at position para relative to the
quinoline nitrogen atom, with compound 31 being 1.5-fold more
potent than 33. Overall, the most potent analogue of the series
against T. cruzi was compound 3, which exhibited an IC50 value of
9.47 mM, 4-fold more potent than the reference compound benz-
nidazole. In addition, six other derivatives turned out to be slightly
more potent or equipotent to benznidazole, with IC50 values around
30 mM. However, all the novel compounds were clearly less selec-
tive than benznidazole for T. cruzi vs mammalian cells, with SITc < 1
for the novel compounds and 14.1 for benznidazole (Table 2).
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agents, with IC50 values in the lowmicromolar range in most cases,
being more potent (up to 5-fold) than the reference compound
potassium antimony (III) tartrate hydrate (Table 2). Thus, these
compounds were more active against L. infantum than against
T. cruzi, with the sole exception of compound 3, the most potent
antichagasic derivative of the series. Even though the novel com-
pounds were 2e25-fold more selective for L. infantum vs
mammalian cells than potassium antimony (III) tartrate hydrate
(SILi¼ 0.1), their selectivity indices were rather low (SILi in the range
0.2e2.5) (Table 2).
Some of the SARs of the leishmanicidal activity of the novel
tricyclic heterofused quinoline analogueswere very similar to those
found for anti-trypanosome activities, with the best substitution
pattern involving the presence of: i) a protonatable 4-(amino-
methyl)phenyl group at the B-ring, with amines 30, 31, 32, 33, and
39 being 1.5 to >31-fold more potent than their nitrile precursors
26, 27, 28, 29, and 38, respectively, and amine 39 being 6- and 8-
fold more potent than the 5-(2-furyl)- and 5-(2-thienyl)-
substituted derivatives 42 and 43, respectively; ii) a ﬁve- or a
seven-membered A-ring, with the pyrroloquinoline 30 and the
azepinoquinoline 32 being approximately 2-fold more potent than
the benzonaphthyridine 31, bearing a six-membered ring A; and iii)
an aromatic B-ring, with compound 38 being >9-fold more potent
than the saturated analogue 37. For this activity, the presence of an
oxygen atom a position 1 of the A-ring led to increased potency
relative to an NH group, with compound 39 being 2-fold more
potent than 31. However, a reverse SAR trend relative to those
found for the anti-trypanosome activities was observed regarding
the presence of a Bn-N group at position 1 of the A-ring and the
isomerization of the chlorine and aminomethyl substituents. Thus,
the presence of a Bn-N group at position 1 of the A-ring was
detrimental for leishmanicidal activity, with compound 3 being 3-
and 5-fold less potent than the NH- and O-substituted counterparts
31 and 39, respectively, whereas the interchange of the chlorine
and aminomethyl substituents from compound 2 to 3 resulted in
decreased potency against L. infantum (4-fold). The position of the
chlorine substituent at the C-ring had no inﬂuence on the leish-
manicidal activity of the novel compounds. Of note, as found when
measuring T. brucei activities, the three ring-open analogues
featuring a protonatable amino group at the side chain, i.e. 35, 49,
and 50, exhibited signiﬁcant leishmanicidal activity, with IC50
values around 15 mM (Table 2).
Themost potent analogues of the series against L. infantumwere
benzonaphthyridines 2, 30, and 32, and pyranoquinoline 39, with
IC50 values in the range 5e8 mM.
3. Conclusion
We have synthesized a series of tricyclic heterofused quinolines,
namely benzo[h][1,6]naphthyridines, pyrrolo[3,2-c]quinolines,
azepino[3,2-c]quinolines, and pyrano[3,2-c]quinolines, through
2e4-step synthetic sequences that involve as the key step an initial
Povarov multicomponent reaction between a cyclic enamide or
enol ether as an activated oleﬁn and a properly substituted aniline
and aromatic aldehyde. The novel compounds have been designed
from benzonaphthyridine 1, a submicromolar inhibitor of AChE
previously developed in our group that has been found to display a
signiﬁcant in vitro activity against T. brucei. Initial structural mod-
iﬁcations around hit 1, including N-dealkylation of the side chain at
position 9 and isomerization by interchange of the chlorine atom at
the para position of the 5-phenyl group and the aminomethyl
substituent at position 9, have led to benzonaphthyridine 3, which
has turned out to be 3-fold more potent than hit 1 against T. brucei.
The structure of compound 3 has been further modiﬁed by N1-debenzylation, A-ring contraction and expansion, bioisosteric
NH / O replacement at position 1, and substitution of the 5-(4-
aminomethyl)phenyl group by 5-(2-furyl) and 5-(2-thienyl). Dur-
ing the synthesis of the target tricyclic compounds, some quinoline
derivatives with a side chain at position 3, arising from opening of
the A-ring, were obtained. To further expand the SAR studies, the
structure of these ring-open derivatives was subsequentlymodiﬁed
by introduction of a protonatable amino group or a neutral cyano
group at the end of the side chain.
Trypanosomatid parasites responsible for HAT, Chagas disease
and visceral leishmaniasis seem to share common metabolic
pathways [14,55], thereby being potentially amenable to treatment
by common drugs. Consistent with this, we have found some
common SAR trends related to the activities of the novel tricyclic
heterofused quinoline analogues against T. brucei, T. cruzi and
L. infantum, with several of these compounds being moderately
potent against two or three of these parasites. Thus, the presence of
an oxidized B-ring featuring a protonatable 4-(aminomethyl)
phenyl group and the bioisosteric NH/ O replacement at position
1 led to higher potencies against the three parasites. Benzonaph-
thyridines 2, 30 and 32, and pyranoquinoline 39 exhibit an inter-
esting multi-trypanosomatid proﬁle, with single digit micromolar
IC50 values against T. brucei and L. infantum and IC50 around 30 mM
against T. cruzi, whereas benzonaphthyridine 3 exhibits single digit
micromolar IC50 values against T. brucei and T. cruzi and IC50 around
30 mM against L. infantum. Interestingly, all of these multi-
trypanosomatid compounds have been predicted to be able to
cross the BBB, which is of utmost importance for the treatment of
late-stage HAT, and have better drug-like properties than hit 1, both
in terms of lower lipophilicity and molecular weight. They also
display higher CNS MPO desirability scores, and hence, are ex-
pected to be endowed with more appropriate and aligned phar-
macokinetic attributes, including low P-gp efﬂux. A signiﬁcant
AChE inhibitory activity in most of these compounds, albeit lower
than that of hit 1, and signiﬁcant toxicity to rat L6 cells are their
main drawbacks, which should be addressed in further lead opti-
mization. To this end, the dual trypanocidal and leishmanicidal
pyranoquinoline 39, which displays the lowest AChE inhibitory
activity, and hence, the lowest potential for cholinergic side effects,
is likely to be the best starting point.
4. Experimental part
4.1. Chemistry. General methods
Melting points were determined in open capillary tubes with a
MFB 595010M Gallenkamp melting point apparatus. 400 MHz 1H/
100.6 MHz 13C NMR spectra were recorded on a Varian Mercury
400 spectrometer. The chemical shifts are reported in ppm (d scale)
relative to solvent signals (CD3OD at 3.31 and 49.0 ppm in the 1H
and 13C NMR spectra, respectively; CDCl3 at 7.26 and 77.0 ppm in
the 1H and 13 C NMR spectra, respectively), and coupling constants
are reported in Hertz (Hz). Assignments given for the NMR spectra
of the new compounds have been carried out by comparison with
the NMR data of 3, 9, 28, 37, 42, 43, 44, 45, 47, and 50, which in turn,
were assigned on the basis of DEPT, COSY 1H/1H (standard pro-
cedures), and COSY 1H/13C (gHSQC or gHMBC sequences) experi-
ments. IR spectra were run on a PerkineElmer Spectrum RX I or on
a Thermo Nicolet Nexus spectrophotometer. Absorption values are
expressed as wavenumbers (cm1); only signiﬁcant absorption
bands are given. Column chromatography was performed on silica
gel 60 AC.C (35e70 mesh, SDS, ref 2000027). Thin-layer chroma-
tography was performed with aluminium-backed sheets with silica
gel 60 F254 (Merck, ref 1.05554), and spots were visualized with UV
light and 1% aqueous solution of KMnO4. NMR spectra of all of the
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nologics of the University of Barcelona (CCiTUB), while elemental
analyses and high resolution mass spectra were carried out at the
Mycroanalysis Service of the IIQAB (CSIC, Barcelona, Spain) with a
Carlo Erba model 1106 analyser, and at the CCiTUB with a LC/MSD
TOF Agilent Technologies spectrometer, respectively. The HPLC
measurements were performed using a HPLC Waters Alliance HT
apparatus comprising a pump (Edwards RV12) with degasser, an
autosampler, a diode array detector and a column as speciﬁed
below. The reverse phase HPLC determinations were carried out on
a YMC-Pack ODS-AQ column (50  4.6 mm, D S. 3 mm, 12 nm).
Solvent A: water with 0.1% formic acid; Solvent B: acetonitrile with
0.1% formic acid. Gradient: 5% of B to 100% of B within 3.5min. Flux:
1.6 mL/min at 50 C. The analytical samples of all of the compounds
that were subjected to pharmacological evaluation were dried at
65 ºC/2 Torr for at least 2 days (standard conditions) and possess a
purity 95% as indicated by their elemental analyses and/or HPLC
measurements.
4.1.1. 1-Benzyl-9-(tert-butoxycarbonylaminomethyl)-5-(4-
chlorophenyl)-1,2,3,4-tetrahydro-2-oxobenzo[h][1,6]naphthyridine
8
To a stirred solution of p-chlorobenzaldehyde, 6 (1.16 g,
8.25 mmol) and aniline 5 (1.83 g, 8.23 mmol) in anhydrous CH3CN
(30 mL), 4 Åmolecular sieves and Sc(OTf)3 (0.81 g, 1.65mmol) were
added. The mixture was stirred at room temperature under argon
atmosphere for 5min and then treatedwith a solution of enamine 4
(1.50 g, 8.01 mmol) in anhydrous CH3CN (16 mL). The resulting
suspension was stirred at room temperature under argon atmo-
sphere for 3 days. Then, the resulting mixture was diluted with sat.
aq. NaHCO3 (150 mL) and extracted with EtOAc (3  200 mL). The
combined organic extracts were dried over anhydrous Na2SO4 and
evaporated under reduced pressure to give a solid residue (4.71 g),
mainly consisting of a diastereomeric mixture of octahy-
drobenzonaphthyridines 7, which was used in the next step
without further puriﬁcation.
To a solution of crude diastereomeric mixture 7 (4.58 g of a
crude of 4.71 g) in anhydrous CHCl3 (150 mL), DDQ (4.85 g,
21.4 mmol) was added. The reaction mixture was stirred at room
temperature under argon atmosphere overnight, diluted with
CH2Cl2 (150 mL) and washed with sat. aq. NaHCO3 (3  250 mL).
The combined organic extracts were dried over anhydrous Na2SO4
and evaporated under reduced pressure to give a solid residue
(5.33 g), which was puriﬁed through column chromatography
(35e70 mm silica gel, hexane/EtOAc mixtures, gradient elution). On
elution with hexane/EtOAc 80:20, compound 8 (1.94 g, 47% yield)
was isolated as a white solid; Rf 0.83 (hexane/EtOAc 1:1).
A solution of 8 (30 mg, 0.06 mmol) in CH2Cl2 (5 mL) was ﬁltered
through a 0.2 mm PTFE ﬁlter and evaporated at reduced pressure.
The solid was washed with pentane (3  5 mL) to give, after drying
under standard conditions, the analytical sample of 8 (27 mg): mp
90e91 C; IR (ATR) n 3347 (NH st), 1691 (C]O, AreCeC and
AreCeN st) cm1; 1H NMR (400MHz, CDCl3) d 1.47 [s, 9H, C(CH3)3],
2.61 (t, J ¼ 6.8 Hz, 2H, 4-H2), 2.90 (t, J ¼ 6.8 Hz, 2H, 3-H2), 4.36 (d,
J ¼ 6.0 Hz, 2H, 9-CH2-NH), 4.96 (br s, 1H, 9-CH2-NH), 5.33 (s, 2H, 1-
CH2-Ar), 7.12 [dd, J ¼ 8.0 Hz, J0 ¼ 1.6 Hz, 2H, 1-CH2-AreC2(6)-H],
7.20e7.29 [complex signal, 3H, 1-CH2-AreC3(5)-H, 1-CH2-
AreC4eH], 7.46 [dm, J ¼ 8.8 Hz, 2H, 5-AreC3(5)-H], 7.53 [dm,
J¼ 8.8 Hz, 2H, 5-AreC2(6)-H], 7.61 (dd, J ¼ 8.8 Hz, J0 ¼ 1.6 Hz, 1H, 8-
H), 7.77 (br s, 1H, 10-H), 8.11 (d, J ¼ 8.8 Hz, 1H, 7-H); 13C NMR
(100.6MHz, CDCl3) d 23.5 (CH2, C3), 28.4 [3CH3, C(CH3)3], 32.7 (CH2,
C4), 44.5 (CH2, 9-CH2-NH), 52.2 (CH2, 1-CH2-Ar), 79.9 [C, C(CH3)3],
119.9 (C, C10a), 120.8 (CH), 127.3 (CH), 127.5 (CH), 128.5 (CH), 128.6
(CH), 130.5 (CH) (AreCH), 121.7 (C, C4a), 129.2 (C, C9), 135.1 (C, 1-
CH2-AreC1), 137.4 (C), 137.5 (C) (5-AreC1, 5-AreC4), 146.8 (C,C6a), 147.7 (C, C5), 155.9 (C), 156.6 (C) (C10b, NCOO), 172.8 (C, C2);
HRMS (ESI), calcd for [C31H3035ClN3O3 þ Hþ] 528.2048, found
528.2045.
4.1.2. N-{1-Benzyl-5-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-
oxobenzo[h][1,6]naphthyridin-9-yl}methanamine 9
Compound 8 (1.94 g, 3.67 mmol) was dissolved in 4M HCl/
dioxane solution (24 mL) at 0 C. The mixture was stirred at room
temperature overnight and concentrated in vacuo. The solid residue
was diluted in water (20 mL), treated with 1N NaOH (20 mL), and
the aqueous phase was extracted with a 10% MeOH/CHCl3 mixture
(3  50 mL). The combined organic extracts were dried over
anhydrous Na2SO4 and evaporated at reduced pressure to give a
crude product (1.42 g), which was puriﬁed through column chro-
matography (35e70 mm silica gel, EtOAc/MeOH/50% aq. NH4OH,
gradient elution). On elution with EtOAc/MeOH/50% aq. NH4OH
98.8:1:0.2 to 94.8:5:0.2, amine 9 (690 mg, 44% yield) was isolated
as a yellow solid; Rf 0.78 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05).
A solution of 9 (130 mg, 0.30 mmol) in CH2Cl2 (5 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 1.58 mL, 0.84 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
9$2HCl (119 mg) as a yellow solid: mp 218e220 C; IR (ATR) n
3500e2500 (max at 3386, 2919, 2850, 2610, þNH and CH st), 1704
(C]O st), 1609, 1590, 1580, 1520, 1503 (C]O, AreCeC and AreCeN
st) cm1; 1H NMR (400 MHz, CD3OD) d 2.83 (br t, J ¼ 6.8 Hz, 2H, 3-
H2), 3.09 (br t, J¼ 6.8 Hz, 2H, 4-H2), 4.28 (s, 2H, 9-CH2-NH2), 4.88 (s,
þNH, þNH3), 5.57 (s, 2H, 1-CH2-Ar), 7.24e7.36 (complex signal, 5H,
1-CH2-AreH), 7.75 [br d, J ¼ 8.0 Hz, 2H, 5-AreC3(5)-H], 7.82 [br d,
J ¼ 8.0 Hz, 2H, 5-AreC2(6)-H], 8.19 (br d, J ¼ 8.8 Hz, 1H, 8-H), 8.29
(d, J ¼ 8.8 Hz, 1H, 7-H), 8.43 (br s, 1H, 10-H); 13C NMR (100.6 MHz,
CD3OD) d 23.2 (CH2, C4), 31.8 (CH2, C3), 43.9 (CH2, 9-CH2-NH2), 54.7
(CH2, 1-CH2-Ar), 121.1 (C, C10a), 123.2 (CH, C7), 124.7 (C, C4a), 127.3
(CH, C10), 128.4 [2CH, 1-CH2-AreC2(6)], 128.8 (CH, 1-CH2-AreC4),
129.9 [2CH, 1-CH2-AreC3(5)], 130.7 [2CH, 5-AreC3(5)], 130.8 (C, 5-
AreC1), 132.5 [2CH, 5-AreC2(6)], 134.9 (C, C9), 135.6 (CH, C8), 138.6
(C, 1-CH2-AreC1), 139.4 (C, 5-AreC4), 140.7 (C, C6a), 154.3 (C, C5),
156.9 (C, C10b), 173.3 (C, C2); HRMS (ESI), calcd for
[C26H2235ClN3O þ Hþ] 428.1524, found 428.1522.
4.1.3. N-{1-Benzyl-5-(4-chlorophenyl)-1,2,3,4-tetrahydrobenzo[h]
[1,6]naphthyridin-9-yl}methanamine 2
To a suspension of Zn(OAc)2 (49 mg, 0.27 mmol) in anhydrous
THF (0.7 mL) (EtO)3SiH (0.10mL, 89mg, 0.54mmol) was added. The
mixture was stirred at room temperature for 30 min and then
treated with a solution of amino lactam 9 (117 mg, 0.27 mmol) in
anhydrous THF (2.1 mL). The reaction mixture was stirred at 65 C
for 48 h in a sealed vessel. The resulting mixture was cooled to
room temperature, poured onto 1N NaOH (5mL), stirred for 10min,
and then extracted with EtOAc (3  15 mL). The combined organic
extracts were dried over anhydrous Na2SO4 and concentrated un-
der reduced pressure to give a solid (313 mg), which was puriﬁed
through column chromatography (35e70 mm silica gel, CH2Cl2/
MeOH/50% aq. NH4OH mixtures, gradient elution). On elution with
CH2Cl2/MeOH/50% aq. NH4OH 98.5:1.5:0.2, amine 2 (74 mg, 66%
yield) was isolated as a white solid; Rf 0.50 (CH2Cl2/MeOH/50% aq.
NH4OH 9:1:0.05).
A solution of 2 (54 mg, 0.13 mmol) in CH2Cl2 (5 mL) was ﬁltered
through a 0.2 mm PTFE ﬁlter and treated with a methanolic solution
of HCl (0.53 N, 2.25 mL, 1.19 mmol). The resulting solution was
evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
2$2HCl (54 mg) as a yellowish solid: mp 230e232 C; IR (ATR) n
3500e2500 (max at 3369, 2918, 2855, 2616, þNH and CH st), 1633,
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(400MHz, CD3OD) d 2.05 (m, 2H, 3-H2), 2.75 (t, J¼ 6.0 Hz, 2H, 4-H2),
3.64 (t, J ¼ 4.8 Hz, 2H, 2-H2), 4.07 (s, 2H, 9-CH2-NH2), 4.85 (s, þNH,
þNH3), 5.32 (s, 2H,1-CH2-Ar), 7.39e7.53 (complex signal, 5H,1-CH2-
AreH), 7.66e7.71 (complex signal, 4H, 5-AreH), 7.94e8.01 (com-
plex signal, 2H, 7-H, 8-H), 8.18 (br s,1H,10-H); 13C NMR (100.6MHz,
CD3OD) d 21.4 (CH2, C3), 26.5 (CH2, C4), 44.2 (CH2, C2), 52.9 (CH2, 9-
CH2-NH2), 61.7 (CH2, 1-CH2-Ar), 115.4 (C, C4a), 118.1 (C, C10a), 121.9
(CH, C7), 128.3 [2CH, 1-CH2-AreC2(6)], 128.5 (CH, 1-CH2-AreC4),
129.4 (CH, C10), 130.48 [2CH, 1-CH2-AreC3(5)], 130.50 [2CH, 5-
AreC3(5)], 131.3 (C, C9), 131.9 [2CH, 5-AreC2(6)], 132.4 (C, 5-
AreC4), 134.5 (CH, C8), 137.0 (C, 1-CH2-AreC1), 138.2 (C, 5-
AreC1), 140.6 (C, C6a), 150.3 (C, C5), 159.7 (C, C10b); HRMS (ESI),
calcd for [C26H243 5ClN3 þ Hþ] 414.1732, found 414.1732; Elemental
analysis, calcd for C26H24ClN3$2HCl$2.2H2O C 59.31%, H 5.82%, N
7.98%, found C 59.70%, H 5.71%, N 7.58%. HPLC purity: 97%.
4.1.4. 4-{1-Benzyl-9-chloro-1,2,3,4-tetrahydro-2-oxobenzo[h][1,6]
naphthyridin-5-yl}benzonitrile 13
It was prepared as described for 8. From 4-chloroaniline, 10
(794 mg, 6.22 mmol), 4-formylbenzonitrile, 11 (816 mg,
6.22 mmol), Sc(OTf)3 (595 mg, 1.21 mmol), and enamine 4 (1.13 g,
6.04 mmol), a solid residue (2.71 g), mainly consisting of a diaste-
reomeric mixture of octahydrobenzonaphthyridines 12, was ob-
tained and used in the next step without further puriﬁcation.
From crude diastereomeric mixture 12 (2.71 g) and DDQ (3.65 g,
16.1 mmol), a solid residue (1.97 g) was obtained and puriﬁed
through column chromatography (35e70 mm silica gel, hexane/
EtOAc mixtures, gradient elution). On elution with hexane/EtOAc
75:25 to 60:40, compound 13 (886 mg, 35% yield) was isolated as a
brown solid; Rf 0.46 (hexane/EtOAc 7:3).
A solution of 13 (396 mg, 0.93 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mm NYL ﬁlter and evaporated at reduced
pressure. The resulting solid was recrystallized from EtOAc (6 mL)
and washed with pentane (3  5 mL) to give, after drying under
standard conditions, the analytical sample of 13 (228mg) as a beige
solid: mp 252e254 C; IR (KBr) n 2228 (CN st), 1687, 1605, 1559,
1543 (C]O, AreCeC and AreCeN st) cm1; 1H NMR (400 MHz,
CDCl3) d 2.64 (t, J ¼ 6.8 Hz, 2H, 40-H2), 2.90 (t, J ¼ 6.8 Hz, 2H, 30-H2),
5.33 (s, 2H, 10-CH2eAr), 7.13 [dm, J¼ 8.4 Hz, 2H, 10eCH2eAreC2(6)-
H], 7.22e7.31 (complex signal, 3H, 10-CH2-AreC3(5)-H, 10-CH2-
AreC4eH), 7.64 (dd, J ¼ 9.2 Hz, J0 ¼ 2.4 Hz, 1H, 80-H), 7.71 (dm,
J¼ 8.4 Hz, 2H) and 7.80 (dm, J¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], 7.92
(d, J ¼ 2.4 Hz, 1H, 100- H), 8.06 (d, J ¼ 9.2 Hz, 1H, 70-H); 13C NMR
(100.6 MHz, CDCl3) d 23.5 (CH2, C30), 32.5 (CH2, C40), 52.2 (CH2, 10-
CH2eAr), 112.8 (C, C1), 118.4 (C, CN), 120.9 (C, C10a0), 122.1 (C, C4a0),
122.2 (CH), 127.2 (2 CH), 127.7 (CH), 128.6 (2 CH), 129.9 (2 CH), 130.6
(CH), 132.1 (CH), 132.3 (2 CH) (AreCH), 132.7 (C, C90), 137.0 (C, 10-
CH2-AreC1), 143.5 (C), 146.4 (C), 146.9 (C) (C4, C6a0, C10b0), 156.2 (C,
C50), 172.3 (C, C20); HRMS (ESI), calcd for [C26H1835ClN3O þ Hþ]
424.1211, found 424.1213.
4.1.5. 4-{1-Benzyl-9-chloro-1,2,3,4-tetrahydrobenzo[h][1,6]
naphthyridin-5-yl}benzylamine 3
A solution of compound 13 (120 mg, 0.28 mmol) in anhydrous
THF (10 mL) was treated with LiAlH4 (71 mg, 1.87 mmol). The re-
action mixture was stirred under reﬂux overnight, cooled to 0 C
with an ice bath and treated dropwise with 1N NaOH (5 mL), then
diluted with H2O (5 mL), and extracted with EtOAc (3 15mL). The
combined organic extracts were dried over anhydrous Na2SO4 and
evaporated under reduced pressure to give a brown oily residue
(210 mg), which was puriﬁed through column chromatography
(35e70 mm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures,
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH
99:1:0.2 to 98:2:0.2, amine 3 (26 mg, 22% yield) was isolated as abeige solid; Rf 0.35 (CH2Cl2/MeOH/NH4OH 9.75:0.25:0.1).
A solution of 3 (26 mg, 0.06 mmol) in CH2Cl2 (40 mL) was
ﬁltered through a 0.2 mm NYL ﬁlter and treated with a methanolic
solution of HCl (2.36 N, 0.12 mL, 0.28 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  2 mL) to give, after drying under standard conditions,
3$2HCl (21 mg) as a beige solid: mp 171e173 C; IR (ATR) n
3500e2500 (max at 3382, 2921, 2850, þNH, NH and CH st), 1633,
1623,1615,1575,1567,1559,1539,1534,1515 (AreCeC and AreCeN
st) cm1; 1H NMR (400 MHz, CD3OD) d 2.07 (m, 2H, 30-H2), 2.76 (t,
J ¼ 6.0 Hz, 2H, 40-H2), 3.68 (t, J ¼ 5.6 Hz, 2H, 20-H2), 4.30 (s, 2H, 1-
CH2-NH2), 4.85 (s, þNH, þNH3) 5.20 (s, 2H,10-CH2eAr), overimposed
in part 7.44 (m,1H,10-CH2-AreC4eH), 7.47 [d, J¼ 7.2 Hz, 2H,10-CH2-
AreC2(6)-H], 7.54 [t, J ¼ 7.2 Hz, 2H, 10-CH2-AreC3(5)-H], 7.77e7.79
[complex signal, 4H, C2(6)-H, C3(5)-H], 7.82 (dd, J ¼ 9.2 Hz,
J0 ¼ 2.0 Hz,1H, 80-H), 7.90 (d, J¼ 9.2 Hz,1H, 70-H), 8.07 (d, J¼ 2.0 Hz,
1H, 100-H); 13C NMR (100.6 MHz, CD3OD) d 21.1 (CH2, C30), 26.7
(CH2, C40), 43.9 (CH2, 1-CH2-NH2), 53.4 (CH2, C20), 61.4 (CH2, 10-
CH2eAr), 115.4 (C, C4a0), 119.1 (C, C10a0), 122.8 (CH, C70), 126.1 (CH,
C100), 127.5 [2 CH, 10-CH2-AreC2(6)]), 129.4 (CH, 10-CH2-AreC4),
130.6 [2 CH,10-CH2-AreC3(5)], 130.8 (2 CH) and 130.9 (2 CH) [C2(6),
C3(5)], 132.1 (C, C90), 134.5 (C, C4), 134.6 (CH, C80), 136.7 (C, 10-CH2-
AreC1), 137.4 (C, C1), 139.0 (C, C6a0), 150.7 (C, C50), 159.0 (C, C10b0);
HRMS (ESI), calcd for [C26H2435ClN3 þ Hþ] 414.1732, found 414.1743;
Elemental analysis, calcd for C26H24ClN3$2HCl$0.75H2O C 62.41%, H
5.54%, found C 62.65%, H 5.70%. HPLC purity: 97%.
4.1.6. 4-{1-(tert-Butoxycarbonyl)-8-chloro-2,3-dihydro-1H-pyrrolo
[3,2-c]quinolin-4-yl}benzonitrile 22
It was prepared as described for 8. From 4-chloroaniline, 10
(1.33 g, 10.4 mmol), 4-formylbenzonitrile, 11 (1.36 g, 10.4 mmol),
Sc(OTf)3 (1.02 g, 2.07 mmol), and enamine 14 (1.80 mL, 1.76 g,
10.4 mmol), a sticky yellow solid residue (5.00 g), mainly consisting
of a diastereomeric mixture of pyrroloquinolines 18, was obtained
and used in the next step without further puriﬁcation.
From crude diastereomeric mixture 18 (5.00 g) and DDQ (4.72 g,
20.8 mmol), a solid residue (4.53 g) was obtained and puriﬁed
through column chromatography (35e70 mm silica gel, hexane/
EtOAc mixtures, gradient elution). On elution with hexane/EtOAc
70:30, compound 22 (2.47 g, 59% yield) was isolated as a grey solid;
Rf 0.60 (hexane/EtOAc 1:1).
A solution of 22 (100 mg, 0.25 mmol) in CH2Cl2 (5 mL) was
ﬁltered through a 0.2 mmPTFE ﬁlter and diluted with hexane/EtOAc
2:1 (6 mL). The resulting solid precipitate was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
the analytical sample of 22 (74 mg) as a grey solid: mp 210e211 C;
IR (ATR) n 2229 (CN st), 1700 (C]O st), 1604, 1564, 1540 (AreCeC
and AreCeN st) cm1; 1H NMR (400 MHz, CDCl3) d 1.59 [s, 9H,
C(CH3)3], 3.31 (t, J¼ 8.0 Hz, 2H, 30-H2), 4.30 (t, J¼ 8.0 Hz, 2H, 20-H2),
7.61 (dd, J ¼ 8.8 Hz, J0 ¼ 2.4 Hz, 1H, 70-H), 7.80 (dm, J ¼ 8.8 Hz, 2H)
and 7.94 (dm, J ¼ 8.8 Hz, 2H) [C2(6)-H, C3(5)-H], 8.05 (d, J ¼ 8.8 Hz,
1H, 60-H), 8.16 (d, J¼ 2.4 Hz, 1H, 90-H); 13C NMR (100.6 MHz, CDCl3)
d 28.2 [3CH3, C(CH3)3], 28.8 (CH2, C30), 51.5 (CH2, C20), 82.9 [C,
C(CH3)3], 112.5 (C, C1), 118.6 (C, CN), 119.6 (C), 124.4 (C) (C3a0, C9a0),
124.9 (CH), 130.3 (CH), 131.4 (CH) (C60, C70, C90), 129.1 (2CH), 132.3
(2CH) [C2(6), C3(5)], 131.1 (C, C80), 143.7 (C), 147.7 (C), 148.1 (C) (C4,
C5a0, C9b0), 153.0 (C), 153.2 (C) (NCOO, C40); HRMS (ESI), calcd for
[C23H2035ClN3O2 þ Hþ] 406.1317, found 406.1308.
4.1.7. 4-{1-(tert-Butoxycarbonyl)-9-chloro-1,2,3,4-tetrahydrobenzo
[h][1,6]naphthyridin-5-yl}benzonitrile 23
It was prepared as described for 8. From 4-chloroaniline, 10
(1.24 g, 9.72 mmol), 4-formylbenzonitrile, 11 (1.27 g, 9.69 mmol),
Sc(OTf)3 (0.95 g, 1.93 mmol), and enamine 15 (1.80 mL, 1.78 g,
9.70 mmol), a yellow solid residue (5.31 g), mainly consisting of a
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and used in the next step without further puriﬁcation.
From crude diastereomeric mixture 19 (5.31 g) and DDQ (4.40 g,
19.4 mmol), a brown residue (4.74 g) was obtained and puriﬁed
through column chromatography (35e70 mm silica gel, hexane/
EtOAc mixtures, gradient elution). On elution with hexane/EtOAc
90:10, compound 23 (2.79 g, 69% yield) was isolated as a white
solid; Rf 0.60 (hexane/EtOAc 1:1).
A solution of 23 (71mg, 0.17mmol) in CH2Cl2 (8 mL) was ﬁltered
through a 0.2 mm PTFE ﬁlter and evaporated at reduced pressure.
The resulting solid was washed with pentane (3  5 mL) to give,
after drying under standard conditions, the analytical sample of 23
(70 mg) as a white solid: mp 146e147 C; IR (ATR) n 2222 (CN st),
1702 (C]O st), 1602, 1578, 1560 (AreCeC and AreCeN st) cm1; 1H
NMR (400MHz, CDCl3) d 1.40 [s, 9H, C(CH3)3], 1.99 (br signal, 2H, 30-
H2), 2.76 (t, J ¼ 6.8 Hz, 2H, 40-H2), 3.20e4.20 (br signal, 2H, 20-H2),
7.58 (dd, J ¼ 9.2 Hz, J0 ¼ 2.4 Hz, 1H, 80-H), 7.69 (dm, J ¼ 8.4 Hz, 2H),
7.79 (dm, J¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], superimposed 7.80 (m,
1H, 100-H), 7.98 (d, J ¼ 9.2 Hz, 1H, 70-H); 13C NMR (100.6 MHz,
CDCl3) d 23.9 (CH2, C30), 25.3 (CH2, C40), 27.9 [3CH3, C(CH3)3)], 44.6
(CH2, C20), 82.3 [C, C(CH3)3], 112.3 (C, C1), 118.6 (C, CN), 123.6
(CH þ C), 124.5 (C), 129.8 (3CH), 131.1 (CH), 132.2 (2CH) [C2(6),
C3(5), C4a0, C70, C80, C100, C10a0), 131.8 (C, C90), 144.1 (C), 144.4 (C),
145.4 (C) (C4, C6a0, C10b0), 153.8 (C, C50), 157.7 (C, NCOO); HRMS
(ESI), calcd for [C24H2235ClN3O2 þ Hþ] 420.1473, found 420.1475.
4.1.8. 4-{1-(tert-Butoxycarbonyl)-10-chloro-2,3,4,5-tetrahydro-1H-
azepino[3,2-c]quinolin-6-yl}benzonitrile 24
It was prepared as described for 8. From 4-chloroaniline, 10
(0.59 g, 4.62 mmol), 4-formylbenzonitrile, 11 (0.61 g, 4.65 mmol),
Sc(OTf)3 (0.46 g, 0.93 mmol), and enamine 16 (0.90 mL, 924 mg,
4.69 mmol), a yellow solid residue (2.33 g), mainly consisting of a
diastereomeric mixture of benzonaphthyridines 20, was obtained
and used in the next step without further puriﬁcation.
From crude diastereomeric mixture 20 (2.33 g) and DDQ (2.11 g,
9.30 mmol), a solid residue (1.99 g) was obtained and puriﬁed
through column chromatography (35e70 mm silica gel, hexane/
EtOAc mixtures, gradient elution). On elution with hexane/EtOAc
80:20, compound 24 (1.58 g, 79% yield) was isolated as a white
solid; Rf 0.58 (hexane/EtOAc 1:1).
A solution of 24 (200 mg, 0.46 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mmPTFE ﬁlter and diluted with hexane/EtOAc
2:1 (3 mL). The solid precipitate was washed with pentane
(3  5 mL) to give, after drying under standard conditions, the
analytical sample of 24 (100 mg) as a white solid: mp 177e179 C;
IR (ATR) n 2223 (CN st), 1698 (C]O st), 1602, 1579, 1564, 1550
(AreCeC and AreCeN st) cm1; 1H NMR (400MHz, CDCl3) d 1.25 [s,
C(CH3)3], 1.46 (m), 1.84e1.94 (complex signal), 1.98e2.16 (complex
signal), 2.70 (tm, J ¼ 14.0 Hz), 2.82 (tm, J ¼ 14.0 Hz), 2.92 (ddm,
J¼ 14.4 Hz, J0 ¼ 5.2 Hz), 4.40 (dm, J¼ 14.4 Hz, 20-H2 minor rotamer),
4.58 (dt, J ¼ 14.0 Hz, J0 ¼ 3.2 Hz, 20-H2 major rotamer), super-
imposed in part 7.61 (dd, J ¼ 9.2 Hz, J0 ¼ 2.4 Hz, 90-H minor
rotamer), 7.63 (dd, J ¼ 9.2 Hz, J0 ¼ 2.4 Hz, 90-H major rotamer),
superimposed in part 7.65 [dm, J ¼ 8.4 Hz, C2(6)-H or C3(5)-H
minor rotamer], 7.70 (dm, J ¼ 8.4 Hz), 7.80 dm, (J ¼ 8.4 Hz)
[C2(6)-H, C3(5)-H major rotamer], 7.78 (d, J ¼ 2.4 Hz, 110-H minor
rotamer), superimposed in part 7.79 [dm, J ¼ 8.4 Hz, C3(5)-H or
C2(6)-H minor rotamer], 7.82 (d, J ¼ 2.4 Hz, 110-H major rotamer),
8.01 (d, J ¼ 9.2 Hz, 80-H minor rotamer) 8.03 (d, J ¼ 9.2 Hz, 80-H
major rotamer); 13C NMR (100.6 MHz, CDCl3) d signiﬁcant signals of
the major rotamer 24.8 (CH2, C40), 28.0 [3CH3, C(CH3)3], 28.6 (CH2),
29.81 (CH2) (C30, C50), 47.3 (CH2, C20), 81.2 [C, C(CH3)3], 112.3 (C, C1),
118.56 (C, CN), 122.2 (C), 125.5 (C) (C5a0, C11a0), 144.9 (C), 145.6 (C),
147.7 (C) (C4, C7a0, C11b0), 152.8 (C, C50), 158.9 (C, NCOO); 13C NMR
(100.6 MHz, CDCl3) d signiﬁcant signals of the minor rotamer 24.9(CH2, C40), 28.3 [3CH3, C(CH3)3], 29.4 (CH2), 29.75 (CH2) (C30, C50),
48.4 (CH2, C20), 81.5 [C, C(CH3)3], 112.2 (C, C1), 118.59 (C, CN), 122.0
(C), 125.7 (C) (C5a’, C11a0), 145.0 (C), 145.8 (C), 147.9 (C) (C4, C7a0,
C11b0), 153.5 (C, C50), 159.0 (C, NCOO); HRMS (ESI), calcd for
[C25H2435ClN3O2 þ Hþ] 434.1630, found 434.1628.
4.1.9. 4-{1-(tert-Butoxycarbonyl)-8-chloro-1,2,3,4-tetrahydrobenzo
[h][1,6]naphthyridin-5-yl}benzonitrile 25
It was prepared as described for 8. From 3-chloroaniline, 17
(1.03 mL, 1.25 g, 9.77 mmol), 4-formylbenzonitrile, 11 (1.27 g,
9.69 mmol), Sc(OTf)3 (0.95 g, 1.93 mmol), and enamine 15 (1.80 mL,
1.78 g, 9.70 mmol), a solid residue (4.90 g), mainly consisting of a
diastereomeric mixture of benzonaphthyridines 21, was obtained
and used in the next step without further puriﬁcation.
From crude diastereomeric mixture 21 (4.90 g) and DDQ (4.40 g,
19.4 mmol), a residue (4.42 g) was obtained and puriﬁed through
column chromatography (35e70 mm silica gel, hexane/EtOAc mix-
tures, gradient elution). On elution with hexane/EtOAc 90:10,
compound 25 (2.53 g, 62% yield) and 4-{3-[3-(tert-butox-
ycarbonylamino)propyl]-7-chloroquinolin-2-yl}benzonitrile, 34
(705 mg, 17% yield) were successively isolated; Rf (26) 0.46; Rf (35)
0.24 (hexane/EtOAc 70:30).
A solution of 25 (2.53 g, 6.04 mmol) in CH2Cl2 (25 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and evaporated at reduced
pressure. The resulting solid was washed with Et2O (3 10mL) and
pentane (3  8 mL) to give, after drying under standard conditions,
the analytical sample of 25 (1.09 g) as a white solid: mp
162e164 C; IR (ATR) n 2223 (CN st), 1698 (C]O st), 1608, 1575,
1561 (AreCeC and AreCeN st) cm1; 1H NMR (400 MHz, CDCl3)
d 1.41 [s, 9H, C(CH3)3], 1.99 (br signal, 2H, 30-H2), 2.75 (t, J ¼ 6.8 Hz,
2H, 40-H2), 3.4e4.4 (br signal, 2H, 20-H2), 7.47 (dd, J ¼ 8.8 Hz,
J0 ¼ 2.0 Hz, 1H, 90-H), 7.69 (dm, J ¼ 8.4 Hz, 2H), 7.79 (dm, J ¼ 8.4 Hz,
2H) [C2(6)-H, C3(5)-H], 7.74 (d, J¼ 8.8 Hz, 100-H), 8.04 (d, J¼ 2.0 Hz,
1H, 70-H); 13C NMR (100.6 MHz, CDCl3) d 23.9 (CH2, C30), 25.2 (CH2,
C40), 28.0 [3CH3, C(CH3)3], 44.8 (CH2, C20), 82.1 [C, C(CH3)3], 112.3 (C,
C1), 118.6 (C, CN), 122.3 (C), 123.0 (C) (C4a0, C10a0), 125.8 (CH), 126.7
(CH), 128.3 (CH) (C70, C90, C100), 129.7 (2CH), 132.2 (2CH) [C2(6),
C3(5)], 134.8 (C, C80), 144.4 (C), 145.0 (C), 147.4 (C) (C4, C6a0, C10b0),
153.9 (C, C50), 158.5 (C, NCOO); HRMS (ESI), calcd for
[C24H2235ClN3O2 þ Hþ] 420.1473, found 420.1469.
A solution of 34 (30 mg, 0.07 mmol) in CH2Cl2 (2 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and evaporated at reduced
pressure. The resulting solid was washed with Et2O (3  5 mL) and
pentane (3  5 mL) to give, after drying under standard conditions,
the analytical sample of 34 (19 mg) as a yellow solid: mp
124e126 C; IR (ATR) n 3358 (NH st), 2229 (CN st), 1680 (C]O st),
1623, 1591, 1519 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CDCl3) d 1.41 [s, 9H, C(CH3)3], 1.71 (tt, J ¼ 7.6 Hz,
J0¼6.4 Hz, 2H, 200-H2), 2.78 (t, J ¼ 7.6 Hz, 2H, 100-H2), 3.06 (dt,
J ¼ J0 ¼ 6.4 Hz, 2H, 300-H2), 4.42 (br s, 2H, NHCOO), 7.52 (dd,
J ¼ 9.2 Hz, J0 ¼ 2.0 Hz, 1H, 60-H), 7.67 (dm, J ¼ 8.4 Hz, 2H), 7.80 (dm,
J¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], 7.76 (d, J¼ 9.2 Hz, 1H, 50-H), 8.08
(br s, 1H, 40-H), 8.09 (d, J ¼ 2.0 Hz, 1H, 80-H); 13C NMR (100.6 MHz,
CDCl3) d 28.4 [3CH3, C(CH3)3], 29.9 (CH2), 31.0 (CH2) (C100, C200), 39.9
(CH2, C300), 79.4 [C, C(CH3)3], 112.4 (C, C1), 118.5 (C, CN), 126.1 (C,
C4a0), 128.2 (2CH), 128.3 (CH), 129.6 (2CH), 132.3 (2CH) [C2(6),
C3(5), C50, C60, C80], 132.7 (C), 135.3 (C) (C70, C8a0), 136.2 (CH, C40),
144.8 (C), 146.8 (C) (C4, C30), 155.8 [C, C20], 159.2 (C, NHCOO); HRMS
(ESI), calcd for [C24H2435ClN3O2 þ Hþ] 422.1630, found 422.1623.
4.1.10. 4-{8-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]quinolin-4-yl}
benzonitrile 26
It was prepared as described for 9. From 22 (877mg, 2.16 mmol)
and 4M HCl/dioxane solution (18 mL), a solid residue (430 mg) was
obtained. Recrystallization from EtOAc/hexane 1:1.5 afforded
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EtOAc 1:1).
A solution of 26 (100 mg, 0.33 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 1.85 mL, 0.98 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
26$HCl (108 mg) as a yellow solid: mp 324e326 C; IR (ATR) n
3500e2500 (max at 3359, 3183, 3023, 2925, 2749, þNH, NH and CH
st), 2228 (CN st),1633,1604,1588,1556,1519 (AreCeC and AreCeN
st) cm1; 1H NMR (400MHz, CD3OD) d 3.42 (t, J¼ 9.0 Hz, 2H, 30-H2),
4.18 (t, J ¼ 9.0 Hz, 2H, 20-H2), 4.85 (s, þNH, NH), 7.90e7.92 (complex
signal, 2H, 60-H, 70-H), 7.97 [br d, J¼ 8.4 Hz, 2H, C3(5)-H], 8.02 [br d,
J ¼ 8.4 Hz, 2H, C2(6)-H], 8.21 (m, 1H, 90-H); 13C NMR (100.6 MHz,
CD3OD) d 27.1 (CH2, C30), 49.4 (CH2, C20),114.0 (C, C3a0),116.0 (C, C1),
118.8 (C, CN), 119.7 (C, C9a0), 122.7 (CH), 124.6 (CH) (C60, C90), 130.7
[2CH, C3(5)], 133.0 (C, C80), 134.2 [2CH, C2(6)], 136.2 (CH, C70), 137.5
(C, C5a0), 140.1 (C, C4), 146.0 (C, C40), 162.6 (C, C9b0); HRMS (ESI),
calcd for [C18H1235ClN3 þ Hþ] 306.0793, found 306.0792; Elemental
analysis, calcd for C18H12ClN3$HCl$1/2H2O C 61.55%, H 4.02%, N
11.96%, found C 61.35%, H 4.07%, N 11.73%. HPLC purity: 94%.
4.1.11. 4-{9-Chloro-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5-
yl}benzonitrile 27
It was prepared as described for 9. From 23 (1.76 g, 4.20 mmol)
and 4MHCl/dioxane solution (29mL), nitrile 27 (915mg, 68% yield)
was obtained as a yellowish solid; Rf 0.60 (hexane/EtOAc 1:1).
A solution of 27 (154 mg, 0.48 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 2.73 mL, 1.45 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
27$HCl (148 mg) as a beige solid: mp 343e344 C; IR (ATR) n
3500e2500 (max at 3170, 3077, 2708, þNH, NH and CH st), 2226
(CN st), 1627, 1584, 1566 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 1.98 (tt, J ¼ 6.0 Hz, J0 ¼ 5.6 Hz, 2H, 30-H2), 2.71
(t, J ¼ 6.0 Hz, 2H, 40-H2), 3.69 (t, J ¼ 5.6 Hz, 2H, 20-H2), 4.85 (s, þNH,
NH), 7.84 (d, J¼ 8.8 Hz,1H, 70-H), 7.85 [br d, J¼ 8.4 Hz, 2H, C3(5)-H],
7.90 (dd, J ¼ 8.8 Hz, J0 ¼ 2.0 Hz, 1H, 80-H), 8.02 [br d, J ¼ 8.4 Hz, 2H,
C2(6)-H], 8.41 (d, J ¼ 2.0 Hz, 1H, 100-H); 13C NMR (100.6 MHz,
CD3OD) d 19.9 (CH2, C30), 24.9 (CH2, C40), 43.0 (CH2, C20), 109.8 (C,
C4a0), 115.8 (C, C1), 117.8 (C, C10a0), 118.9 (C, CN), 122.8 (CH), 122.9
(CH) (C70, C100), 131.3 [2CH, C3(5)], 133.6 (C, C90), 134.0 [2CH, C2(6)],
135.1 (CH, C80), 137.4 (C, C6a0), 138.0 (C, C4), 150.3 (C, C50), 154.7 (C,
C10b0); HRMS (ESI), calcd for [C19H1435ClN3 þ Hþ] 320.0949, found
320.0948; Elemental analysis, calcd for C19H14ClN3$HCl C 64.06%, H
4.24%, N 11.80%, found C 63.79%, H 4.22%, N 11.79%. HPLC purity
>99%.
4.1.12. 4-{10-Chloro-2,3,4,5-tetrahydro-1H-azepino[3,2-c]quinolin-
6-yl}benzonitrile 28
It was prepared as described for 9. From 24 (997mg, 2.30 mmol)
and 4MHCl/dioxane solution (16mL), nitrile 28 (392mg, 51% yield)
was obtained as a beige solid; Rf 0.50 (hexane/EtOAc 1:1).
A solution of 28 (392 mg, 1.17 mmol) in CH2Cl2 (8 mL) was
ﬁltered through a 0.2 mmPTFE ﬁlter and diluted with hexane/EtOAc
2:1 (3mL). The solid precipitate (aliquot of 111mg of a total amount
of 232 mg) was treated with a methanolic solution of HCl (0.53 N,
1.88 mL, 1.00 mmol). The resulting solution was evaporated at
reduced pressure and the solid was washed with pentane
(3  5 mL) to give, after drying under standard conditions, 28$HCl
(114 mg) as a yellowish solid: mp 338e340 C; IR (ATR) n
3500e2500 (max at 3167, 3085, 3033, 2930, 2795, 2715, 2635, þNH,
NH and CH st), 2222 (CN st), 1627, 1599, 1573, 1560, 1501 (AreCeC
and AreCeN st) cm1; 1H NMR (400MHz, CD3OD) d 2.04 (m, 2H, 40-H2), 2.19 (m, 2H, 30-H2), 2.85 (m, 2H, 50-H2), 3.96 (m, 2H, 20-H2), 4.85
(s, þNH, NH), superimposed in part 7.82 (d, J¼ 8.8 Hz,1H, 80-H), 7.84
[br d, J¼ 8.4 Hz, 2H, C3(5)-H], 7.89 (dd, J¼ 8.8 Hz, J0 ¼ 2.4 Hz,1H, 90-
H), 8.02 [br d, J¼ 8.4 Hz, 2H, C2(6)-H], 8.43 (d, J¼ 2.4 Hz,1H,110-H);
13C NMR (100.6 MHz, CD3OD) d 26.3 (CH2, C40), 27.7 (CH2, C30), 27.9
(CH2, C50), 44.9 (CH2, C20), 114.7 (C, C5a’), 115.9 (C, C1), 118.8 (C, CN),
119.3 (C, C11a0), 122.7 (CH, C80), 123.0 (CH, C110), 131.4 [2CH, C3(5)],
133.8 (C, C100), 134.0 [2CH, C2(6)], 135.1 (CH, C90), 137.3 (C, C7a0),
138.8 (C, C4), 152.6 (C, C60), 160.0 (C, C11b0); HRMS (ESI), calcd for
[C20H1635ClN3 þ Hþ] 334.1105, found 334.1106; Elemental analysis,
calcd for C20H16ClN3$HCl$0.3H2O C 63.94%, H 4.72%, N 11.18%, found
C 63.72%, H 4.56%, N 10.85%. HPLC purity >99%.
4.1.13. 4-{8-Chloro-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5-
yl}benzonitrile 29
It was prepared as described for 9. From 25 (2.24 g, 5.34 mmol)
and 4M HCl/dioxane solution (37 mL), nitrile 29 (1.60 g, 94% yield)
was obtained as a yellow solid; Rf 0.34 (hexane/EtOAc 1:1).
A solution of 29 (275 mg, 0.86 mmol) in CH2Cl2 (15 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 5.16 mL, 2.73 mmol). The resulting solution
was evaporated at reduced pressure and the solid was recrystal-
lized fromMeOH/hexane 1:3.75 (1.9 mL) and washed with pentane
(3  8 mL) to give, after drying under standard conditions, 29$HCl
(166 mg) as a brown solid: mp 360e362 C; IR (ATR) n 3500e2500
(max at 3148, 3078, 3035, 2905, 2734, þNH, NH and CH st), 2228
(CN st), 1629, 1583, 1500 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 1.98 (tt, J ¼ 6.0 Hz, J0 ¼ 5.2 Hz, 2H, 30-H2), 2.70
(t, J ¼ 6.0 Hz, 2H, 40-H2), 3.69 (t, J ¼ 5.2 Hz, 2H, 20-H2), 4.85 (s, þNH,
NH), 7.67 (dd, J¼ 8.8 Hz, J0 ¼ 1.6 Hz, 1H, 90-H), superimposed in part
7.84 (m, 1H, 70-H), 7.85 (br d, J ¼ 7.6 Hz, 2H), 8.02 (br d, J ¼ 7.6 Hz,
2H) [C2(6)-H, C3(5)-H], 8.29 (d, J ¼ 8.8 Hz, 1H, 100-H); 13C NMR
(100.6 MHz, CD3OD) d 20.0 (CH2, C30), 24.9 (CH2, C40), 43.1 (CH2,
C20), 109.7 (C, C4a0), 115.4 (C), 115.9 (C) (C1, C10a0), 118.9 (C, CN),
120.0 (CH), 125.5 (CH), 128.4 (CH) (C70, C90, C100), 131.3 (2CH), 134.0
(2CH) [C2(6), C3(5)], 138.0 (C), 139.6 (C), 140.8 (C) (C4, C6a0, C80),
150.5 (C, C50), 155.4 (C, C10b0); HRMS (ESI), calcd for
[C19H1435ClN3 þ Hþ] 320.0949, found 320.0946; Elemental analysis,
calcd for C19H14ClN3$HCl C 64.06%, H 4.24%, N 11.80%, found C
64.02%, H 4.41%, N 11.85%. HPLC purity >99%.
4.1.14. 4-{8-Chloro-2,3-dihydro-1H-pyrrolo[3,2-c]quinolin-4-yl}
benzylamine 30
It was prepared as described for 3. From nitrile 26 (216 mg,
0.71 mmol) and LiAlH4 (0.13 g, 3.43 mmol), a yellow solid residue
(210 mg) was obtained and puriﬁed by column chromatography
(35e70 mm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures,
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH
99:1:0.2 to 98.5:1.5:0.2, the amine 30 (163 mg, 74% yield) was
isolated as a beige solid; Rf 0.22 (CH2Cl2/MeOH/50% aq. NH4OH
9:1:0.05).
A solution of 30 (138 mg, 0.45 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 7.54 mL, 4.00 mmol). The resulting solution
was evaporated at reduced pressure and the solid was recrystal-
lized fromMeOH/EtOAc 1:3 (4 mL), and then washed with pentane
(3  5 mL) to give, after drying under standard conditions, 30$2HCl
(108 mg) as a yellow solid: mp 319e320 C; IR (ATR) n 3500e2500
(max at 3364, 3111, 3043, 2943, 2614, þNH, NH and CH st), 1638,
1605, 1573, 1529, 1511 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 3.42 (t, J¼ 8.8 Hz, 2H, 30-H2), 4.17 (t, J¼ 8.8 Hz,
2H, 20-H2), 4.29 (s, 2H,1-CH2-NH2), 4.85 (s, þNH, þNH3, NH), 7.78 (br
d, J ¼ 8.4 Hz, 2H), 7.90 (br d, J ¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], 7.86
(dd, J ¼ 9.2 Hz, J0 ¼ 2.4 Hz, 1H, 70-H), 7.95 (d, J ¼ 9.2 Hz, 1H, 60-H),
8.19 (m, 1H, 90-H); 13C NMR (100.6 MHz, CD3OD) d 27.4 (CH2, C30),
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122.7 (CH, C60), 124.6 (CH, C90), 130.4 (2CH), 131.0 (2CH) [C2(6),
C3(5)], 132.7 (C, C4), 133.8 (C, C80), 135.9 (CH, C70), 137.7 (C, C1),
140.0 (C, C5a0), 147.2 (C, C40), 162.4 (C, C9b0); HRMS (ESI), calcd for
[C18H1635ClN3 þ Hþ] 310.1106, found 310.1101; Elemental analysis,
calcd for C18H16ClN3$2HCl$1.5H2O C 52.76%, H 5.17%, N 10.26%,
found C 52.63%, H 5.21%, N 9.91%. HPLC purity >99%.
4.1.15. 4-{9-Chloro-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5-
yl}benzylamine 31
It was prepared as described for 3. From nitrile 27 (720 mg,
2.25 mmol) and LiAlH4 (0.43 g, 11.3 mmol), a white solid residue
(892 mg) was obtained and puriﬁed by column chromatography
(35e70 mm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures,
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH
97:3:0.2 to 95:5:0.2, the amine 31 (632 mg, 87% yield) was isolated
as a white solid; Rf 0.18 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05).
A solution of 31 (632 mg, 1.95 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 33 mL, 17.5 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  10 mL) to give, after drying under standard condi-
tions, 31$2HCl (640 mg) as a beige solid: mp 346e347 C; IR (ATR) n
3500e2500 (max at 3028, 2987, 2941, þNH, NH and CH st), 1612,
1573, 1511 (AreCeC and AreCeN st) cm1; 1H NMR (400 MHz,
CD3OD) d 1.97 (tt, J¼ 6.4 Hz, J0 ¼ 5.2 Hz, 2H, 30-H2), 2.74 (t, J¼ 6.4 Hz,
2H, 40-H2), 3.69 (t, J ¼ 5.2 Hz, 2H, 20-H2), 4.30 (s, 2H, 1-CH2-NH2),
4.86 (s, þNH, þNH3, NH), 7.75 (br d, J ¼ 8.4 Hz, 2H), 7.78 (br d,
J ¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], 7.86 (dd, J ¼ 9.2 Hz, J0 ¼ 2.0 Hz,
1H, 80-H), 7.89 (d, J¼ 9.2 Hz,1H, 70-H), 8.41 (d, J¼ 2.0 Hz,1H,100-H);
13C NMR (100.6 MHz, CD3OD) d 20.0 (CH2, C30), 25.1 (CH2, C40), 42.9
(CH2, C20), 43.9 (CH2, 1-CH2-NH2), 109.7 (C, C4a0), 117.7 (C, C10a0),
122.8 (CH, C70), 122.9 (CH, C100), 130.7 (2CH), 130.9 (2CH) [C2(6),
C3(5)], 133.4 (C, C90), 134.3 (C, C4), 134.8 (CH, C80), 137.4 (2C, C1,
C6a0), 151.6 (C, C50), 154.5 (C, C10b0); HRMS (ESI), calcd for
[C19H1835ClN3 þ Hþ] 324.1262, found 324.1263; Elemental analysis,
calcd for C19H18ClN3$2HCl$1/2H2O C 56.24%, H 5.22%, N 10.36%,
found C 56.44%, H 5.25%, N 10.14%. HPLC purity >99%.
4.1.16. 4-{10-Chloro-2,3,4,5-tetrahydro-1H-azepino[3,2-c]quinolin-
6-yl}benzylamine 32
It was prepared as described for 3. From nitrile 28 (172 mg,
0.52 mmol) and LiAlH4 (0.10 g, 2.64 mmol), a yellow solid residue
(363 mg) was obtained and puriﬁed by column chromatography
(35e70 mm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures,
gradient elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH
99:1:0.2, impure amine 32 (189mg) was obtained. Recrystallization
from hexane/EtOAc 2:1 (3 mL) afforded pure amine 32 (97 mg, 55%
yield) as a white solid; Rf 0.20 (CH2Cl2/MeOH/50% aq. NH4OH
9:1:0.05).
A solution of 32 (97 mg, 0.29 mmol) in CH2Cl2 (5 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 4.88 mL, 2.59 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
32$2HCl (98 mg) as a yellowish solid: mp 310e311 C; IR (ATR) n
3500e2500 (max at 3379, 3219, 3028, 2936, þNH, NH and CH st),
1627, 1586, 1511 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 2.02 (m, 2H, 40-H2), 2.18 (m, 2H, 30-H2), 2.88
(m, 2H, 50-H2), 3.96 (m, 2H, 20-H2), 4.30 (s, 2H, 1-CH2-NH2), 4.86 (s,
þNH, þNH3, NH), 7.74 (br d, J¼ 8.4 Hz, 2H), 7.78 (br d, J¼ 8.4 Hz, 2H)
[C2(6)-H, C3(5)-H], 7.84e7.90 (complex signal, 2H, 80-H, 90-H), 8.44
(m, 1H, 110-H); 13C NMR (100.6 MHz, CD3OD) d 26.4 (CH2, C40), 27.8
(CH2, C30), 28.0 (CH2, C50), 43.9 (CH2, 1-CH2-NH2), 44.9 (CH2, C20),
114.7 (C, C5a0), 119.2 (C, C11a0), 122.7 (CH, C80), 123.0 (CH, C110),130.8 (2CH), 131.1 (2CH) [C2(6), C3(5)], 133.6 (C, C100), 134.8 (CH,
C90), 135.1 (C, C4), 137.3 (C) and 137.5 (C) (C1, C7a0), 153.9 (C, C60),
159.8 (C, C11b0); HRMS (ESI), calcd for [C20H2035ClN3 þ Hþ] 338.1419,
found 338.1416; Elemental analysis, calcd for
C20H20ClN3$2HCl$2.5H2O C 52.70%, H 5.97%, N 9.22%, found C
53.02%, H 5.69%, N 8.72%. HPLC purity >99%.
4.1.17. 4-{8-Chloro-1,2,3,4-tetrahydrobenzo[h][1,6]naphthyridin-5-
yl}benzylamine 33
It was prepared as described for 3. From nitrile 29 (1.17 g,
3.66 mmol) and LiAlH4 (0.69 g, 18.2 mmol), a yellow solid residue
(3.07 g) was obtained. An aliquot of this crude product (1.50 g) was
puriﬁed by column chromatography (35e70 mm silica gel, EtOAc/
MeOH/50% aq. NH4OH mixtures, gradient elution). On elution with
EtOAc/MeOH/50% aq. NH4OH 98:2:0.2, the amine 33 (390 mg, 67%
yield) was isolated; Rf 0.29 (EtOAc/MeOH/50% aq. NH4OH 7:3:0.05).
A solution of 33 (390 mg, 1.20 mmol) in CH2Cl2 (20 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 20.4 mL, 10.8 mmol). The resulting solu-
tion was evaporated at reduced pressure and the solid was washed
with pentane (3  15 mL) to give, after drying under standard
conditions, 33$2HCl (400 mg) as a yellowish solid: mp
305e307 C; IR (ATR) n 3500e2500 (max at 3369, 3212, 2926,
2869, 2614, þNH, NH and CH st), 1625, 1583, 1516 (AreCeC and
AreCeN st) cm1; 1H NMR (400 MHz, CD3OD) d 1.97 (tt, J ¼ 6.0 Hz,
J0 ¼ 5.6 Hz, 2H, 30-H2), 2.74 (t, J ¼ 6.0 Hz, 2H, 40-H2), 3.70 (t,
J ¼ 5.6 Hz, 2H, 20-H2), 4.30 (s, 2H, 1-CH2-NH2), 4.85 (s, þNH, þNH3,
NH), 7.63 (dd, J ¼ 9.2 Hz, J0 ¼ 2.0 Hz, 1H, 90-H), 7.75 (br d,
J ¼ 8.4 Hz, 2H), 7.78 (br d, J ¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], 7.90
(d, J ¼ 2.0 Hz, 1H, 70-H), 8.32 (d, J ¼ 9.2 Hz, 1H, 100-H); 13C NMR
(100.6 MHz, CD3OD) d 20.0 (CH2, C30), 25.0 (CH2, C40), 43.0 (CH2,
C20), 43.9 (CH2, 1-CH2-NH2), 109.5 (C, C4a0), 115.3 (C, C10a0), 119.9
(CH), 125.5 (CH), 128.2 (CH) (C70, C90, C100), 130.8 (2CH), 130.9
(2CH) [C2(6), C3(5)], 134.3 (C), 137.4 (C), 139.5 (C), 140.5 (C) (C1, C4,
C6a0, C80), 151.7 (C, C50), 155.1 (C, C10b0); HRMS (ESI), calcd for
[C19H1835ClN3 þ Hþ] 324.1262, found 324.1258; Elemental analysis,
calcd for C19H18ClN3$2HCl$1.8H2O C 53.17%, H 5.54%, N 9.79%,
found C 53.56%, H 5.54%, N 9.34%. HPLC purity: 98%.
4.1.18. 4-[3-(3-Aminopropyl)-7-chloroquinolin-2-yl]benzonitrile 35
It was prepared as described for 9. From 34 (705 mg, 1.67 mmol)
and 4M HCl/dioxane solution (12 mL), amino nitrile 35 (486 mg,
90% yield) was obtained; Rf 0.17 (EtOAc/MeOH/50% aq. NH4OH
7:3:0.05).
A solution of 35 (109 mg, 0.34 mmol) in CH2Cl2 (8 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.80 N, 1.27 mL, 1.02 mmol). The resulting solution
was evaporated at reduced pressure and the solid was recrystal-
lized from MeOH/EtOAc 1:4 (3 mL) and washed with pentane
(3  5 mL) to give, after drying under standard conditions, 35$2HCl
(70 mg) as a red solid: mp 153e154 C; IR (ATR) n 3500e2500 (max
at 3369, 2954, 2609, þNH, NH and CH st), 2226 (CN st), 1698, 1639,
1607, 1591, 1555, 1534, 1500 (AreCeC and AreCeN st) cm1; 1H
NMR (400 MHz, CD3OD) d 1.99 (tt, J¼ 8.0 Hz, J0 ¼ 7.6 Hz, 2H, 200-H2),
superimposed in part 2.93 (t, J ¼ 7.6 Hz, 2H), 2.97 (t, J ¼ 8.0 Hz, 2H)
(100-H2, 300-H2), 4.88 (s, þNH3, þNH), 7.92 (dd, J ¼ 8.8 Hz, J0 ¼ 2.0 Hz,
1H, 60-H), 7.96 (br d, J ¼ 8.0 Hz, 2H), 8.07 (br d, J ¼ 8.0 Hz, 2H)
[C2(6)-H, C3(5)-H], 8.23 (d, J ¼ 2.0 Hz, 1H, 80-H), 8.32 (d, J ¼ 8.8 Hz,
1H, 50-H), 9.10 (s, 1H, 40-H); 13C NMR (100.6 MHz, CD3OD) d 28.7
(CH2), 29.8 (CH2) (C100, C200), 40.0 (CH2, C300), 116.0 (C, C1), 118.9 (C,
CN),122.4 (CH),131.46 (CH),131.8 (CH) (C50, C60, C80),128.6 (C, C4a0),
131.51 (2CH), 134.09 (2CH) [C2(6), C3(5)], 135.4 (C), 138.7 (C), 141.0
(C), 141.1 (C) (C4, C30, C70, C8a0), 145.8 (CH, C40), 157.6 (C, C20); HRMS
(ESI), calcd for [C19H1635ClN3 þ Hþ] 322.1106, found 322.1103;
Elemental analysis, calcd for C19H16ClN3$2HCl$1.2H2O C 54.81%, H
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4.1.19. 4-{9-Chloro-3,4-dihydro-2H-pyrano[3,2-c]quinolin-5-yl}
benzonitrile 38
It was prepared as described for 8. From 4-chloroaniline, 10
(1.51 g, 11.8 mmol), 4-formylbenzonitrile, 11 (1.56 g, 11.9 mmol),
Sc(OTf)3 (1.18 g, 2.40 mmol), and 3,4-dihydro-2H-pyran, 36
(1.08 mL, 994 mg, 11.8 mmol), a solid residue (4.72 g) was obtained
and puriﬁed by column chromatography (35e70 mm silica gel,
hexane/EtOAc mixtures, gradient elution). On elution with hexane/
EtOAc 80:20 to 50:50, a 1:1 diastereomeric mixture 37 (3.65 g, 95%
yield) was isolated as a white solid. After a second column chro-
matography separation of 1.00 g of diastereomeric mixture 37
(35e70 mm silica gel, hexane/EtOAc mixtures, gradient elution),
pure all-cis-diatereoisomer (90 mg) was isolated as awhite solid; Rf
0.43 (hexane/EtOAc 7:3).
A solution of all-cis-37 (90 mg, 0.28 mmol) in CH2Cl2 (5 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and evaporated at reduced
pressure. The resulting solid was washed with pentane (3  5 mL)
to give, after drying under standard conditions, the analytical
sample of all-cis-37 (85 mg) as a white solid: mp 284e285 C; IR
(ATR) n 3348 (NH st), 2225 (CN st), 1604, 1575 (AreCeC and
AreCeN st) cm1; 1H NMR (400MHz, CDCl3) d 1.16e1.22 (m,1H, 40-
Ha), 1.42e1.56 (complex signal, 3H, 30-Ha, 30-Hb, 40-Hb), 2.17 (m, 1H,
4a0-H), 3.41 (ddd, J ¼ J0 ¼ 11.2 Hz, J00 ¼ 3.2 Hz, 1H, 20-Ha), 3.62 (dm,
J ¼ 11.2 Hz, 1H, 20-Hb), 3.86 (br s, 1H, NH), 4.72 (d, J ¼ 2.4 Hz, 1H, 50-
H), 5.27 (d, J ¼ 5.6 Hz, 1H,10b0-H), 6.56 (d, J ¼ 8.4 Hz, 1H, 70-H), 7.06
(ddd, J ¼ 8.4 Hz, J0 ¼ 2.4 Hz, J00 ¼ 0.8 Hz, 1H, 80-H), 7.40 (dd,
J ¼ 2.4 Hz, J0 ¼ 0.8 Hz, 1H, 100-H), 7.53 [dm, J ¼ 8.4 Hz, 2H, C3(5)-H],
7.68 [dm, J ¼ 8.4 Hz, 2H, C2(6)-H]; 13C NMR (100.6 MHz, CDCl3)
d 18.0 (CH2, C40), 25.1 (CH2, C30), 38.5 (CH, C4a0), 59.2 (CH, C50), 60.8
(CH2, C20), 72.1 (CH, C10b0), 111.6 (C, C1), 116.0 (CH, C70), 118.6 (C,
CN), 121.7 (C, C10a0), 123.9 (C, C90), 127.3 (CH, C100), 127.5 [2CH,
C3(5)], 128.2 (CH, C80), 132.3 [2CH, C2(6)], 143.0 (C, C6a0), 146.3 (C,
C4); HRMS (ESI), calcd for [C19H1735ClN2O þ Hþ] 325.1102, found
325.1101; Elemental analysis, calcd for C19H17ClN2O C 70.26%, H
5.28%, N 8.62%, found C 70.34%, H 5.37%, N 8.80%. HPLC purity >99%.
From diastereomeric mixture 37 (2.70 g, 8.31 mmol) and DDQ
(3.77 g, 16.6 mmol), a solid residue (2.55 g) was obtained and pu-
riﬁed through column chromatography (35e70 mm silica gel, hex-
ane/EtOAc mixtures, gradient elution). On elution with hexane/
EtOAc 80:20, compound 38 (1.09 g, 41% yield) was isolated as a
white solid; Rf 0.57 (hexane/EtOAc 1:1).
A solution of 38 (200 mg, 0.62 mmol) in CH2Cl2 (15 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 3.53 mL, 1.87 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  10 mL) to give, after drying under standard condi-
tions, 38$HCl (200 mg) as a beige solid: mp 222e224 C; IR (ATR) n
3650e2500 (max at 3628, 3342, 3085, 3061, 2921, 2560, þNH and
CH st), 2231 (CN st), 1634, 1602, 1576, 1505 (AreCeC and AreCeN
st) cm1; 1H NMR (400 MHz, CD3OD) d 2.20 (tt, J ¼ 6.0 Hz, J ¼
5.2 Hz, 2H, 30-H2), 2.84 (t, J ¼ 6.0 Hz, 2H, 40-H2), 4.82 (t, J ¼ 5.2 Hz,
2H, 20-H2), 4.87 (s, þNH), 7.97 (br d, J ¼ 8.0 Hz, 2H), 8.08 (br d,
J ¼ 8.0 Hz, 2H) [C2(6)-H, C3(5)-H], overimposed in part 8.07 (dm,
J ¼ 8.8 Hz, 1H, 80-H), 8.15 (d, J ¼ 8.8 Hz, 1H, 70-H), 8.42 (d, J¼ 2.0 Hz,
1H, 100-H); 13C NMR (100.6 MHz, CD3OD) d 21.4 (CH2, C30), 23.3
(CH2, C40), 71.5 (CH2, C20), 115.8 (C, C4a0), 116.6 (C, C1), 118.7 (C, CN),
122.0 (C, C10a0), 123.09 (CH), 123.13 (CH) (C70, C100), 131.5 (2CH),
134.1 (2CH) [C2(6), C3(5)], 136.0 (C, C90), 136.2 (CH, C80), 136.5 (C,
C4), 138.0 (C, C6a0), 155.9 (C, C50), 166.5 (C, C10b0); HRMS (ESI), calcd
for [C19H1335ClN2O þ Hþ] 321.0789, found 321.0786; Elemental
analysis, calcd for C19H13ClN2O$HCl$0.4H2O C 62.62%, H 4.09%, N
7.69%, found C 62.79%, H 4.26%, N 7.48%. HPLC purity >99%.4.1.20. 4-{9-Chloro-3,4-dihydro-2H-pyrano[3,2-c]quinolin-5-yl}
benzylamine 39
It was prepared as described for 3. From nitrile 38 (1.00 g,
3.12 mmol) and LiAlH4 (59 mg, 1.55 mmol), a residue (1.29 g) was
obtained and puriﬁed by column chromatography (35e70 mm silica
gel, EtOAc/MeOH/50% aq. NH4OH mixtures, gradient elution). On
elution with EtOAc/MeOH/50% aq. NH4OH 95:5:0.2 to 80:20:0.2,
the amine 39 (595 mg, 59% yield) was isolated as a yellow solid; Rf
0.14 (EtOAc/MeOH/50% aq. NH4OH 9:1:0.05).
A solution of 39 (595 mg, 1.84 mmol) in CH2Cl2 (25 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 31 mL, 16.4 mmol). The resulting solution
was evaporated at reduced pressure and the solid was recrystal-
lized from MeOH/hexane 1:4 (5 mL) and washed with pentane
(3  20 mL) to give, after drying under standard conditions,
39$2HCl (720 mg) as a beige solid: mp 153e155 C; IR (ATR) n
3500e2500 (max at 3374, 2858, 2706, 2614, þNH and CH st), 1634,
1615, 1604, 1580, 1513 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 2.18 (tt, J ¼ 6.4 Hz, J0 ¼ 5.2 Hz, 2H, 30-H2), 2.85
(t, J ¼ 6.4 Hz, 2H, 40-H2), 4.32 (s, 2H, 1-CH2-NH2), 4.80 (t, J ¼ 5.2 Hz,
2H, 20-H2), 4.86 (s, þNH, þNH3), 7.82 (d, J ¼ 8.4 Hz, 2H), 7.86 (d,
J ¼ 8.4 Hz, 2H) [C2(6)-H, C3(5)-H], 8.04 (dd, J ¼ 8.8 Hz, J0 ¼ 2.4 Hz,
1H, 80-H), 8.15 (d, J¼ 8.8 Hz,1H, 70-H), 8.40 (d, J¼ 2.4 Hz,1H,100-H);
13C NMR (100.6 MHz, CD3OD) d 21.5 (CH2, C30), 23.6 (CH2, C40), 43.8
(CH2, 1-CH2-NH2), 71.3 (CH2, C20), 115.7 (C, C4a0), 121.9 (C, C10a0),
123.0 (CH), 123.3 (CH) (C70, C100), 130.8 (2CH), 131.1 (2CH) [C2(6),
C3(5)], 133.2 (C, C4), 135.7 (C, C90), 135.9 (CH, C80), 138.17 (C), 138.23
(C) (C1, C6a0), 157.4 (C, C50), 166.0 (C, C10b0); HRMS (ESI), calcd for
[C19H1735ClN2O þ Hþ] 325.1102, found 325.1096; Elemental analysis,
calcd for C19H17ClN2O$2HCl$1.1H2O C 54.65%, H 5.12%, N 6.71%,
found C 54.96%, H 5.66%, N 6.44%. HPLC purity: 96%.
4.1.21. 9-Chloro-5-(2-furyl)-3,4-dihydro-2H-pyrano[3,2-c]
quinoline 42
It was prepared as described for 8. From 4-chloroaniline, 10
(1.52 g, 11.9 mmol), furan-2-carboxaldehyde, 40 (0.98 mL, 1.14 g,
11.8 mmol), Sc(OTf)3 (1.18 g, 2.40 mmol), and 3,4-dihydro-2H-py-
ran, 36 (1.08 mL, 994 mg, 11.8 mmol), and heating the reaction
mixture at 50 C, a brown oily residue (4.67 g) was obtained and
used in the next step without further puriﬁcation.
From this crude (4.67 g) and DDQ (5.39 g, 23.7 mmol), a brown
solid residue (4.22 g) was obtained and puriﬁed through column
chromatography (35e70 mm silica gel, hexane/EtOAc mixtures,
gradient elution). On elution with hexane/EtOAc 80:20, compound
42 (916 mg, 27% yield) was isolated as a yellowish solid. On elution
with hexane/EtOAc 50:50, 3-[6-chloro-2-(2-furyl)quinolin-3-yl]-1-
propanol, 44 (1.01 g, 30% yield) was isolated as a yellowish solid; Rf
(42) 0.51; Rf (44) 0.35 (hexane/EtOAc 1:1).
Compound 42 (916 mg, 3.21 mmol) was recrystallized from
hexane/EtOAc 57:43 (7 mL), taken in CH2Cl2 (15 mL), ﬁltered
through a 0.2 mm PTFE ﬁlter and treated with a methanolic solution
of HCl (0.53 N, 11 mL, 5.83 mmol). The resulting solution was
evaporated at reduced pressure and the solid was washed with
pentane (3  15 mL) to give, after drying under standard condi-
tions, 42$HCl (585 mg) as a yellowish solid: mp 243e245 C; IR
(ATR) n 3500e2400 (max at 3085, 2435, þNH and CH st),1629,1602,
1580, 1514 (AreCeC and AreCeN st) cm1; 1H NMR (400 MHz,
CD3OD) d 2.30 (tt, J¼ 6.4 Hz, J0 ¼ 5.6 Hz, 2H, 3-H2), 3.17 (t, J¼ 6.4 Hz,
2H, 4-H2), 4.79 (t, J ¼ 5.6 Hz, 2H, 2-H2), 4.85 (s, þNH), 6.96 (dd,
J ¼ 3.6 Hz, J0 ¼ 1.6 Hz, 1H, 40-H), 7.72 (d, J ¼ 3.6 Hz, 1H, 30-H), 7.99
(dd, J¼ 8.8 Hz, J0 ¼ 2.4 Hz,1H, 8-H), 8.18 (d, J¼ 1.6 Hz,1H, 50-H), 8.26
(d, J ¼ 8.8 Hz, 1H, 7-H), 8.29 (d, J ¼ 2.4 Hz, 1H, 10-H); 13C NMR
(100.6 MHz, CD3OD) d 21.3 (CH2, C3), 23.7 (CH2, C4), 70.8 (CH2, C2),
113.4 (C, C4a), 115.3 (CH, C40), 121.2 (C, C10a), 122.7 (CH, C30), 122.8
(CH, C7), 122.9 (CH, C10), 135.3 (C, C9), 135.9 (CH, C8), 137.7 (C, C6a),
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(ESI), calcd for [C16H1235ClNO2 þ Hþ] 286.0629, found 286.0629;
Elemental analysis, calcd for C16H12ClNO2$HCl C 59.65%, H 4.07%, N
4.35%, found C 59.72%, H 4.00%, N 4.46%. HPLC purity: 97%.
A solution of 44 (100 mg, 0.35 mmol) in CH2Cl2 (7 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 2.1 mL, 1.11 mmol). The resulting solution
was evaporated at reduced pressure and the solid was recrystal-
lized from MeOH/hexane 1:2 (4.5 mL) and washed with pentane
(3  5 mL) to give, after drying under standard conditions, 44$HCl
(110 mg) as a brown solid: mp 202e203 C; IR (ATR) n 3500e2400
(max at 3384, 3121, 3072, 3053, 2927, 2487, þNH, OH, and CH st),
1696, 1633, 1589, 1556, 1524 (AreCeC and AreCeN st) cm1; 1H
NMR (400 MHz, CD3OD) d 2.03 (tt, J ¼ 8.0 Hz, J0 ¼ 6.0 Hz, 2H, 2-H2),
3.30 (t, J¼ 8.0 Hz, 2H, 3-H2), 3.76 (t, J¼ 6.0 Hz, 2H,1-H2), 4.88 (s, OH
and þNH), 6.99 (dd, J ¼ 3.6 Hz, J ¼ 1.6 Hz, 1H, 400-H), 7.93 (d,
J ¼ 3.6 Hz, 1H, 300-H), 8.05 (dd, J ¼ 9.2 Hz, J0 ¼ 2.4 Hz, 1H, 70-H), 8.21
(d, J ¼ 1.6 Hz, 1H, 500-H), 8.28 (d, J ¼ 2.4 Hz, 1H, 50-H), 8.38 (d,
J¼ 9.2 Hz,1H, 80-H), 8.93 (s,1H, 40-H); 13C NMR (100.6MHz, CD3OD)
d 30.6 (CH2, C3), 32.8 (CH2, C2), 61.8 (CH2, C1), 115.6 (CH, C400), 123.2
(CH, C300), 123.3 (CH, C80),128.3 (CH, C50), 129.4 (C, C4a0), 136.0 (CH,
C70), 136.2 (C, C60), 136.4 (C, C8a0), 137.1 (C, C30), 144.7 (C, C20), 145.6
(C, C200), 146.5 (CH, C40), 150.4 (CH, C500); HRMS (ESI), calcd for
[C16H1435ClNO2 þ Hþ] 288.0786, found 288.0785; Elemental analysis,
calcd for C16H14ClNO2$HCl C 59.28%, H 4.66%, N 4.32%, found C
58.92%, H 4.68%, N 4.10%.
4.1.22. 9-Chloro-3,4-dihydro-5-(2-thienyl)-2H-pyrano[3,2-c]
quinoline 43
It was prepared as described for 8. From 4-chloroaniline, 10
(1.52 g, 11.9 mmol), thiophene-2-carboxaldehyde, 41 (1.11 mL,
1.33 g, 11.9 mmol), Sc(OTf)3 (1.17 g, 2.38 mmol), and 3,4-dihydro-
2H-pyran, 36 (1.08 mL, 994 mg, 11.8 mmol), and heating the reac-
tion mixture at 80 C, a brown oily residue (3.64 g) was obtained
and used in the next step without further puriﬁcation.
From this crude (3.64 g) and DDQ (5.40 g, 23.8 mmol), a residue
(4.07 g) was obtained and puriﬁed through column chromatog-
raphy (35e70 mm silica gel, hexane/EtOAc mixtures, gradient
elution). On elution with hexane/EtOAc 90:10, compound 43
(1.43 g, 40% yield) was isolated. On elution with hexane/EtOAc
60:40, 3-[6-chloro-2-(2-thienyl)quinolin-3-yl]-1-propanol, 45
(854 mg, 24% yield) was isolated; Rf (43) 0.70 (hexane/EtOAc 7:3); Rf
(45) 0.34 (hexane/EtOAc 1:1).
A solution of 43 (500 mg, 1.66 mmol) in CH2Cl2 (10 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 9.4 mL, 4.98 mmol). The resulting solution
was evaporated at reduced pressure and the solid was recrystal-
lized from MeOH/EtOAc 1:2 (3 mL) and washed with pentane
(3  8 mL) to give, after drying under standard conditions, 43$HCl
(469 mg) as a yellowish solid: mp 224e225 C; IR (ATR) n
3500e2500 (max at 3245, 3056, 2935, 2603, þNH and CH st), 1629,
1602, 1569, 1530 (AreCeC and AreCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 2.22 (tt, J ¼ 6.0 Hz, J0 ¼ 5.4 Hz, 2H, 3-H2), 3.08
(t, J ¼ 6.0 Hz, 2H, 4-H2), 4.79 (t, J ¼ 5.4 Hz, 2H, 2-H2), 4.88 (s, þNH),
7.43 (dd, J ¼ 5.2 Hz, J0 ¼ 4.0 Hz, 1H, 40-H), 7.88 (dd, J ¼ 4.0 Hz,
J0 ¼ 1.2 Hz, 1H, 30-H), 8.02 (dd, J ¼ 8.8 Hz, J0 ¼ 2.4 Hz, 1H, 8-H), 8.08
(dd, J¼ 5.2 Hz, J0 ¼ 1.2 Hz,1H, 50-H), 8.16 (d, J¼ 8.8 Hz,1H, 7-H), 8.35
(d, J ¼ 2.4 Hz, 1H, 10-H); 13C NMR (100.6 MHz, CD3OD) d 21.5 (CH2,
C3), 24.1 (CH2, C4), 71.1 (CH2, C2), 115.7 (C, C4a), 121.7 (C, C10a),
123.0 (2CH, C7, C10), 129.5 (CH, C40), 131.9 (C, C20), 134.2 (CH, C50),
134.9 (CH, C30), 135.5 (C, C9), 136.0 (CH, C8), 138.1 (C, C6a), 151.6 (C,
C5), 165.9 (C, C10b); HRMS (ESI), calcd for [C16H1235ClNOS þ Hþ]
302.0401, found 302.0399; Elemental analysis, calcd for
C16H12ClNOS$HCl C 56.81%, H 3.87%, N 4.14%, S 9.48%, found C
56.99%, H 3.85%, N 3.98%, S 9.27%. HPLC purity: 97%.A solution of 45 (411 mg, 1.35 mmol) in CH2Cl2 (4.5 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 8.1 mL, 4.29 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
45$HCl (110 mg) as a yellowish solid: mp 198e199 C; IR (ATR) n
3500e2400 (max at 3337, 3076, 3029, 2918, 2886, 2476, þNH, OH
and CH st), 1633, 1583, 1538, 1514 (AreCeC and AreCeN st) cm1;
1H NMR (400 MHz, CD3OD) d 1.92 (tt, J ¼ 8.0 Hz, J0 ¼ 6.0 Hz, 2H, 2-
H2), 3.21 (t, J ¼ 8.0 Hz, 2H, 3-H2), 3.63 (t, J ¼ 6.0 Hz, 2H, 1-H2), 4.92
(s, OH and þNH), 7.43 (dd, J¼ 5.2 Hz, J0 ¼ 4.0 Hz, 1H, 400-H), 7.90 (dd,
J ¼ 4.0 Hz, J0 ¼ 1.2 Hz, 1H, 300-H), 8.07 (dd, J ¼ 9.2 Hz, J0 ¼ 2.0 Hz, 1H,
70-H), superimposed in part 8.08 (dd, J ¼ 5.2 Hz, J0 ¼ 1.2 Hz, 1H, 500-
H), 8.28 (d, J¼ 9.2 Hz,1H, 80-H), 8.34 (d, J¼ 2.0 Hz,1H, 50-H), 9.01 (s,
1H, 40-H); 13C NMR (100.6 MHz, CD3OD) d 30.4 (CH2, C3), 33.7 (CH2,
C2), 61.8 (CH2, C1), 123.6 (CH, C80), 128.3 (CH, C50), 129.6 (CH, C400),
130.2 (C, C4a0), 132.4 (C, C200), 134.3 (CH, C500), 135.1 (CH, C300), 135.9
(CH, C70), 136.7 (C, C60), 137.6 (C, C8a0), 138.6 (C, C30), 146.2 (CH, C40),
151.9 (C, C20); HRMS (ESI), calcd for [C16H1435ClNOS þ Hþ] 304.0557,
found 304.0555; Elemental analysis, calcd for C16H14ClNOS$HCl.1/
5H2O C 55.89%, H 4.51%, N 4.07%, found C 55.86%, H 4.73%, N 3.55%.
4.1.23. N-(tert-butyldimethylsilyloxy)-N-[3-(6-chloro-2-(2-thienyl)
quinolin-3-yl)propyl]-4-methylbenzenesulfonamide 46
To a solution of alcohol 45 (400 mg, 1.32 mmol) in anhydrous
toluene (4 mL) and THF (1.2 mL), N-(tert-butyldimethylsilyloxy)-4-
methylbenzenesulfonamide (397 mg, 1.32 mmol) and PPh3
(691 mg, 2.63 mmol) were added. The mixture was cooled to 0 C
and treated dropwise with DEAD (40% solution in toluene, 0.86 mL,
1.98 mmol). The reaction mixture was stirred at room temperature
for 5 min, concentrated at reduced pressure and puriﬁed through
column chromatography (35e70 mm silica gel, hexane/EtOAc mix-
tures, gradient elution). On elution with hexane/EtOAc 90:10,
slightly impure 46 (913 mg) was isolated; Rf 0.60 (hexane/EtOAc
1:1); mp 91e92 C; IR (ATR) n 1594, 1548, 1522 (AreCeC and
AreCeN st), 1359, 1168 (SO2) cm1; 1H NMR (400 MHz, CDCl3)
d 0.09 [s, 6H, Si(CH3)2], 0.72 [s, 9H, Si[C(CH3)3]], 1.80 (tt,
J ¼ J0 ¼ 7.4 Hz, 2H, 2-H2), 2.25 (s, 3H, tosyl CH3), 2.81 (t, J ¼ 7.2 Hz,
2H), 2.90 (t, J ¼ 7.6 Hz, 2H) (1-H2 and 3-H2), 6.97 (dd, J ¼ 4.8 Hz,
J0 ¼ 4.0 Hz, 1H, 400-H), 7.09e7.18 (complex signal), 7.20e7.24
(complex signal) [4H, 300-H, 500-H, and tosyl-C3(5)-H], 7.42 (dd,
J ¼ 9.2 Hz, J0 ¼ 2.0 Hz, 1H, 70-H), 7.51 [br d, J ¼ 8.4 Hz, 2H, tosyl-
C2(6)-H], 7.57 (d, J ¼ 2.0 Hz, 1H, 50-H), 7.74 (s, 1H, 40-H), 7.85
(d, J ¼ 9.2 Hz, 1H, 80-H); 13C NMR (100.6 MHz, CDCl3) d e 4.1 [2CH3,
Si(CH3)3], 18.4 [C, SiC(CH3)3], 21.8 (CH3, tosyl CH3), 26.1 [3CH3,
SiC(CH3)3], 27.3 (CH2, C2), 30.8 (CH2, C3), 55.4 (CH2, C1), signiﬁcant
aromatic signals: 125.7 (CH, C80), 129.5 [2CH, tosyl-C3(5)], 130.0
[2CH, tosyl-C2(6)], 132.4 (C), 132.8 (C) (C60, C8a0), 136.0 (CH, C40),
144.8 (C, C30), 152.9 (C, C20); HRMS (ESI), calcd for
[C29H3535ClN2O3S2Si þ Hþ] 587.1620, found 587.1596.
4.1.24. 3-[6-Chloro-2-(2-thienyl)quinolin-3-yl]propanenitrile 47
To a solution of 46 (450 mg of a total amount of 913 mg of
slightly impure 46, obtained from 1.32 mmol of alcohol 45) in
anhydrous CH3CN (8 mL), CsF (233 mg, 1.53 mmol) was added. The
reaction mixture was stirred at 60 C for 2.5 h, diluted with satu-
rated aq. NH4Cl (20 mL), and extracted with EtOAc (2  20 mL). The
combined organic extracts were washed with brine (50 mL), dried
over anhydrous Na2SO4 and evaporated at reduced pressure to give
a crude (252 mg), which was puriﬁed through column chroma-
tography (35e70 mm silica gel, hexane/EtOAc mixtures, gradient
elution). On elution with hexane/EtOAc 70:30, nitrile 47 (164 mg,
84% overall yield from alcohol 45) was isolated as a yellowish solid;
Rf 0.57 (hexane/EtOAc 1:1).
A solution of 47 (32 mg, 0.11 mmol) in CH2Cl2 (4.5 mL) was
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solution of HCl (0.53 N, 1.7 mL, 0.90 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
47$HCl (34 mg) as a yellowish solid: mp 65e67 C; IR (ATR) n
3600e2400 (max at 3371, 3111, 3070, 2925, 2853, 2599, þNH and
CH st), 2243 (CN st), 1636, 1591, 1540 (areCeC and areCeN st)
cm1; 1H NMR (400 MHz, CD3OD) d 2.89 (t, J ¼ 5.6 Hz, 2H, 2-H2),
3.46 (m, 2H, 3-H2), 4.92 (s, þNH), 7.42 (m, 1H, 400-H), 7.86 (br d,
J ¼ 2.8 Hz, 1H, 300-H), 8.02e8.08 (complex signal, 2H, 70-H, 500-H),
8.25 (d, J ¼ 8.8 Hz, 1H, 80-H), 8.33 (br s, 1H, 50-H), 9.01 (s, 1H, 40-H);
13C NMR (100.6 MHz, CD3OD) d 17.8 (CH2, C2), 29.5 (CH2, C3), 119.8
(C, C1), 125.7 (CH, C80), 128.2 (CH, C50), 129.6 (CH, C400), 129.9 (C,
C4a0), 133.3 (CH, C500), 133.8 (CH, C300), 134.3 (C, C30), 134.8 (C, C200),
135.3 (CH, C70), 136.2 (C, C60), 140.2 (C, C8a0), 144.2 (CH, C40), 152.6
(C, C20); HRMS (ESI), calcd for [C16H1135ClN2S þ Hþ] 299.0404, found
299.0402; Elemental analysis, calcd for C16H11ClN2S$HCl.1.3H2O C
53.58%, H 4.10%, found C 53.80%, H 3.79%; HPLC purity: 96%.
4.1.25. 3-[6-Chloro-2-(2-thienyl)quinolin-3-yl]propyl
methanesulfonate 48
A solution of alcohol 45 (494 mg, 1.63 mmol) and freshly
distilled Et3N (271 mL, 197 mg, 1.94 mmol) was cooled to 0 C and
treated dropwise with MsCl (163 mL, 241 mg, 2.11 mmol) over
10 min. The reaction mixture was stirred at 0 C for 30 min, poured
into a mixture of H2O (30 mL) and ice (6 mL), and extracted with
CH2Cl2 (2  20 mL). The combined organic extracts were washed
with saturated aq. NaHCO3 (20 mL), brine (20 mL), dried over
anhydrous Na2SO4 and evaporated at reduced pressure to give
crude mesylate 48 (633 mg), which was used in the next step
without further puriﬁcation; Rf 0.50 (hexane/EtOAc 1:1); mp
130e132 C; IR (ATR) n 1593, 1548, 1522 (areCeC and areCeN st),
1358, 1339, 1169 (SO2) cm1; 1H NMR (400 MHz, CDCl3) d 2.11 (tt,
J ¼ 7.6 Hz, J0 ¼ 6.0 Hz, 2H, 2-H2), 3.00 (s, 3H, CH3SO3), 3.21 (t,
J ¼ 7.6 Hz, 2H, 3-H2), 4.27 (t, J ¼ 6.0 Hz, 2H, 1-H2), 7.20 (dd,
J ¼ 4.8 Hz, J0 ¼ 4.0 Hz, 1H, 400-H), 7.55 (d, J ¼ 4.8 Hz, 1H, 500-H), 7.62
(d, J ¼ 4.0 Hz, 1H, 300-H), superimposed in part 7.64 (dd, J ¼ 9.2 Hz,
J0 ¼ 2.0 Hz, 1H, 70-H), 7.77 (d, J ¼ 2.0 Hz, 1H, 50-H), 8.03 (s, 1H, 40-H),
8.15 (d, J ¼ 9.2 Hz, 1H, 80-H); 13C NMR (100.6 MHz, CDCl3) d 29.3
(CH2), 29.5 (CH2) (C2, C3), 37.4 (CH3, CH3SO3), 68.6 (CH2, C1), 125.6
(C þ CH, C4a0, C80), 127.7 (C, C200), 127.9 (CH), 129.0 (CH), 129.1 (CH),
129.6 (CH), 131.2 (CH) (C50, C70, C300, C400, C500), 132.4 (C), 133.0 (C)
(C60, C8a0), 137.2 (CH, C40), 143.7 (C, C30), 152.2 (C, C20); HRMS (ESI),
calcd for [C17H1635ClNO3S2 þ Hþ] 382.0333, found 382.0335.
4.1.26. N-{3-[6-Chloro-2-(2-thienyl)quinolin-3-yl]propyl}
pyrrolidine 49
To a solution of crude mesylate 48 (296 mg of a total amount of
633 mg of crude mesylate 48 obtained from 1.63 mmol of alcohol
45) in anhydrous DMF (10 mL), pyrrolidine (0.13 mL, 111 mg,
1.56 mmol) and K2CO3 (322 mg, 2.33 mmol) were added. The re-
action mixture was stirred at 85 C overnight, cooled to room
temperature, treated with saturated aq. NaHCO3 (20 mL), and
extracted with EtOAc (3  30 mL). The combined organic extracts
were washed with H2O (3  15 mL), dried over anhydrous Na2SO4
and evaporated at reduced pressure to give a crude (165mg), which
was puriﬁed through column chromatography (35e70 mm silica
gel, EtOAc/MeOH/50% aq. NH4OH mixtures, gradient elution). On
elution with EtOAc/MeOH/50% aq. NH4OH 80:20:0.2, amine 49
(84 mg, 31% overall yield from alcohol 45) was isolated; Rf 0.10
(hexane/EtOAc 1:1).
A solution of 49 (84 mg, 0.24 mmol) in CH2Cl2 (4.5 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 4.0 mL, 2.12 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed withpentane (3  5 mL) to give, after drying under standard conditions,
49$2HCl (88 mg) as a yellowish solid: mp 136e138 C; IR (ATR) n
3200e2600 (max at 3076, 2941, 2931, 2858, þNH and CH st), 1594,
1548, 1525 (areCeC and areCeN st) cm1; 1H NMR (400 MHz,
CD3OD) d 2.04 (br signal, 2H, 2-H2), 2.12e2.26 [complex signal, 4H,
pyrrolidine 3(4)-H2], 3.10 (br signal, 2H), 3.24 (br signal, 4H), 3.66
(br signal, 2H) [1-H2, 3-H2, pyrrolidine 2(5)-H2], 7.45 (br s, 1H, 400-
H), 7.93 (br s, 1H, 300-H), 8.04e8.12 (complex signal, 2H, 70-H, 500-H),
8.30 (d, J ¼ 8.4 Hz, 1H, 80-H), 8.39 (br s, 1H, 50-H), 9.14 (s, 1H, 40-H);
13C NMR (100.6 MHz, CD3OD) d 24.1 [2CH2, pyrrolidine C3(4)], 27.1
(CH2, C2), 30.6 (CH2, C3), 55.19 (CH2, C1), 55.21 [2CH2, pyrrolidine
C2(5)], 123.8 (CH, C80), 128.5 (CH, C50), 129.8 (CH, C400), 130.2 (C,
C4a0), 132.2 (C, C200), 134.4 (CH, C500), 135.4 (CH, C300), 136.1 (CH, C70),
136.66 (C), 136.73 (C) (C60, C8a0), 137.9 (C, C30), 146.3 (CH, C40), 152.0
(C, C20); HRMS (ESI), calcd for [C20H2135ClN2S þ Hþ] 357.1187, found
357.1187; Elemental analysis, calcd for C20H21ClN2S$2HCl.3H2O C
49.64%, H 6.04%, N 5.79%, found C 49.98%, H 5.72%, N 5.29%; HPLC
purity: 96%.
4.1.27. N-{3-[6-Chloro-2-(2-thienyl)quinolin-3-yl]propyl}-N,N-
diethylamine 50
It was prepared as described for 49. From crude mesylate 48
(293 mg of a total amount of 585 mg of crude mesylate 48 obtained
from 0.82 mmol of alcohol 45) and freshly distilled Et2NH (320 mL,
226 mg, 3.09 mmol), a crude product (157 mg) was obtained and
puriﬁed by column chromatography (35e70 mm silica gel, EtOAc/
MeOH/50% aq. NH4OH mixtures, gradient elution). On elution with
EtOAc/MeOH/50% aq. NH4OH 80:20:0.2, the amine 50 (24 mg, 16%
overall yield from alcohol 45) was isolated; Rf 0.10 (hexane/EtOAc
1:1).
A solution of 50 (24 mg, 66.9 mmol) in CH2Cl2 (4.5 mL) was
ﬁltered through a 0.2 mm PTFE ﬁlter and treated with a methanolic
solution of HCl (0.53 N, 1.2 mL, 0.64 mmol). The resulting solution
was evaporated at reduced pressure and the solid was washed with
pentane (3  5 mL) to give, after drying under standard conditions,
50$2HCl (24 mg) as a yellowish solid: mp 98e100 C; IR (ATR) n
3500e2500 (max at 3422, 3117, 3071, 2933, 2863, 2648, þNH and
CH st), 1637, 1592, 1540 (areCeC and areCeN st) cm1; 1H NMR
(400 MHz, CD3OD) d 1.32 [m, 6H, N(CH2CH3)2], 2.16 (br signal, 2H,
2-H2), 3.16e3.28 [complex signal, 8H, 1-H2, 3-H2, N(CH2CH3)2], 4.89
(s, þNH), 7.43 (br s, 1H, 400-H), 7.90 (br s, 1H, 300-H), 8.04e8.09
(complex signal, 2H, 70-H, 500-H), 8.25 (d, J ¼ 8.8 Hz, 1H, 80-H), 8.36
(br s, 1H, 50-H), 9.08 (s, 1H, 40-H); 13C NMR (100.6 MHz, CD3OD)
d 9.24 [CH3, N(CH2CH3)2], 25.2 (CH2, C2), 30.7 (CH2, C3), 48.6 [CH2,
N(CH2CH3)2], 52.2 (CH2, C1), 124.3 (CH, C80), 128.4 (CH, C50), 129.7
(CH, C400), 130.2 (C, C4a0), 133.1 (C, C200), 134.0 (CH, C500), 134.9 (CH,
C300), 135.8 (CH, C70), 136.5 (C), 136.6 (C) (C60, C8a0), 138.5 (C, C30),
145.6 (CH, C40), 152.2 (C, C20); HRMS (ESI), calcd for
[C20H2335ClN2S þ Hþ] 359.1343, found 359.1347; Elemental analysis,
calcd for C20H23ClN2S$2HCl.2.5H2O C 50.37%, H 6.34%, N 5.87%,
found C 50.55%, H 6.07%, N 5.38%; HPLC purity: > 99%.
4.2. Biological assays
4.2.1. T. brucei culturing and evaluation of trypanocidal activity
Bloodstream form T. brucei (strain 221) was cultured at 37 C in
modiﬁed Iscove's medium [56]. Trypanocidal activity was assessed
by growing parasites in the presence of various concentrations of
the novel compounds and determining the levels which inhibited
growth by 50% (IC50) and 90% (IC90). T. brucei in the logarithmic
phase of growth were diluted back to 2.5  104 mL1 and aliquoted
into 96-well plates. The compounds were then added at a range of
concentrations and the plates incubated at 37 C. Each drug con-
centration was tested in triplicate. Resazurin was added after 48 h
and the plates incubated for a further 16 h and the plates then read
O. Di Pietro et al. / European Journal of Medicinal Chemistry 105 (2015) 120e137136in a Spectramax plate reader. Results were analysed using Graph-
Pad Prism.
4.2.2. T. cruzi and L. infantum culturing and evaluation of
trypanocidal and leishmanicidal activity
Stock solutions of the novel compounds in DMSOwere prepared
at concentrations of 20 mg mL1, with the ﬁnal DMSO concentra-
tion being lower than 2% for all experiments. Trypanocidal and
leishmanicidal activity was assessed by growing parasites in the
presence of various concentrations of the novel compounds and
determining the levels which inhibited growth by 50% (IC50). The
IC50 was determined from a least-squares linear regression of
growth rate versus log drug concentrations.
T. cruzi strain MHOM/ES/2203/BCN590 (Tcl) was used. Epi-
mastigote forms were cultured in liver infusion tryptose broth (LIT)
with 10% foetal bovine serum and 1% penicillin (100 U mL1) e
streptomycin (100 mg mL1) solution (Sigma P-4333) at 28 C.
For evaluation of T. cruzi activity serial dilutions of the novel
compounds in LIT culture medium were aliquoted in 96-well mi-
crotiter plates (Costar 3596). Then 4  106 mL1 epimastigotes
culture medium in the logarithmic growth phase were added to
each well, incubating at 28 C for 72 h. Benznidazole was used as
the reference drug at concentrations from 2.50 mM to 2.42 mM.
Parasite inhibition for each drug concentration was determined
using an automated cell counter (TC20 BIO-RAD). All assays were
performed in duplicate at least twice.
L. infantum strain MCAN/ES/92/BCN722, isolated from a dog
with visceral leishmaniosis, was used. Promastigote forms were
cultured in Schneider's insect medium (Sigma S-8995), pH 7, with
20% heat-inactivated foetal calf serum, 25 mg mL1 gentamycin
solution (Sigma G-1397), and 1% penicillin (100 U mL1) e strep-
tomycin (100 mg mL1) solution (Sigma P-4333) at 26 C. Serial
dilutions of the novel compounds in Schneider culture medium
were performed in 96-well microtiter plates (Costar 3596). Then
106 mL1 promastigotes in their logarithmic growth phase was
added to each well (100 mL/well), incubating at 26 C for 48 h.
Potassium antimony (III) tartrate hydrate was used as the reference
drug at concentrations from 815 to 0.80 mM. Growth was measured
through the acid phosphatase activity [57]. All assays were per-
formed in duplicate at least twice.
4.2.3. Cytotoxic activity against rat skeletal myoblast L6 cells
Cytotoxicity against mammalian cells was assessed using
microtitre plates following a described procedure [58]. Brieﬂy, rat
skeletal muscle L6 cells were seeded at 1  104 mL1 in 200 mL of
growth medium containing different compound concentrations.
The plates were incubated for 6 days at 37 C and 20 mL resazurin
was then added to each well. After a further 8 h incubation, the
ﬂuorescence was determined using a Spectramax plate reader.
4.2.4. Acetylcholinesterase inhibitory activity
The inhibitory activity against E. electricus (Ee) AChE (Sigma-
eAldrich) was evaluated spectrophotometrically by the method of
Ellman et al. [59]. The reactions took place in a ﬁnal volume of
300 mL of 0.1 M phosphate-buffered solution pH 8.0, containing
EeAChE (0.03 u/mL) and 333 mM5,50-dithiobis(2-nitrobenzoic) acid
(DTNB; SigmaeAldrich) solution used to produce the yellow anion
of 5-thio-2-nitrobenzoic acid. Inhibition curves were performed in
duplicates using at least 10 increasing concentrations of inhibitors
and preincubated for 20 min at 37 C before adding the substrate.
One duplicate sample without inhibitor was always present to yield
100% of AChE activity. Then substrate, acetylthiocholine iodide
(450 mM; SigmaeAldrich), was added and the reaction was devel-
oped for 5 min at 37 C. The colour production was measured at
414 nm using a labsystems Multiskan spectrophotometer.Data from concentrationinhibition experiments of the in-
hibitors were calculated by non-linear regression analysis, using
the GraphPad Prism program package (GraphPad Software; San
Diego, USA), which gave estimates of the IC50 (concentration of
drug producing 50% of enzyme activity inhibition). Results are
expressed as mean ± S.E.M. of at least 4 experiments performed in
duplicate.
4.2.5. Determination of brain permeability: PAMPA-BBB assay
The in vitro permeability (Pe) of the novel compounds and
fourteen commercial drugs through lipid extract of porcine brain
membrane was determined by using a parallel artiﬁcial membrane
permeation assay [50]. Commercial drugs and the target com-
pounds were tested using a mixture of PBS:EtOH 70:30. Assay
validation was made by comparing experimental and described
permeability values of the commercial drugs, which showed a good
correlation: Pe (exp)¼ 1.583 Pe (lit)e 1.079 (R2¼ 0.9305). From this
equation and the limits established by Di et al. for BBB permeation,
three ranges of permeability were established: compounds of high
BBB permeation (CNSþ): Pe (106 cm s1) > 5.25; compounds of
low BBB permeation (CNSe): Pe (106 cm s1) < 2.09; and com-
pounds of uncertain BBB permeation (CNS±): 5.25 > Pe
(106 cm s1) > 2.09.
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